Document:

EX-10.4

 Exhibit 10.4 

PATENT ACQUISITION AND LICENSE TERMINATION AGREEMENT 

This PATENT ACQUISITION AND LICENSE TERMINATION AGREEMENT (hereinafter “Agreement”), effective as of June 26, 2009 (the
“Effective Date”), by and between Synecor LLC, a Delaware limited liability company (hereinafter “Synecor”), Barosense, Inc., a Delaware corporation (hereinafter “Barosense”), and TransEnterix,
Inc., a Delaware corporation (hereinafter “TransEnterix”) (Synecor, Barosense and TransEnterix, each a “Party” and collectively the “Parties”). 

RECITALS 
 Barosense and Synecor
entered into a license agreement effective December 8, 2004 (the “Barosense License,” defined below) under which Synecor granted Barosense license rights under the Barosense-related patents listed at Exhibit A and to other
intellectual property. 
 TransEnterix and Synecor entered into a license agreement effective December 31, 2007 (the
“TransEnterix License,” defined below) under which Synecor granted TransEnterix license rights under the TransEnterix-related patents listed at Exhibit B and Exhibit C and to other intellectual property. 

Synecor desires to transfer ownership of the Barosense-related patents to Barosense, and in partial exchange therefor, Barosense desires to
terminate the Barosense License. 
 Synecor desires to transfer ownership of the TransEnterix-related patents to TransEnterix, and in
partial exchange therefor, TransEnterix desires to terminate the TransEnterix License. 
 NOW, THEREFORE, in consideration of the promises
and mutual covenants contained herein, the adequacy of which is acknowledged, the Parties agree as follows: 
 1. DEFINITIONS 

1.1 “Assigned Patents” means, collectively, the Exhibit A Patents, the Exhibit B Patents and the Exhibit C
Patents. 
 1.2 “Barosense License” shall mean the Amended and Restated IP Transfer and Exclusive License Agreement dated
December 8, 2004 between Barosense and Synecor. 
 1.3 “Barosense Services” shall mean the services provided by Synecor
to Barosense during the term ending on December 8, 2006. 
 1.4 “Barosense Work Product” shall mean all documents,
records, files, materials and prototypes created or developed by Synecor, solely or jointly with Barosense, in the performance of Barosense Services. Barosense Work Product includes, but is not limited to, Patent Documents for each of the
Exhibit A Patents. 

 1.5 “Encumbrance” means with respect to any Patent, any mortgage, lien, pledge,
charge, security interest, express license, or encumbrance of any kind whatsoever in respect of such Patent. 
 1.6 “Exhibit A
Patents” means (a) the Patents listed at Exhibit A; and (b) any and all Patents that are part of the same Patent Family as one or more of the Patents listed at Exhibit A; provided, however, that “Exhibit A
Patents” does not include any Patents listed in Exhibit B or Exhibit C. 
 1.7 “Exhibit B Patents” means
(a) the Patents listed at Exhibit B; and (b) any and all Patents that are part of the same Patent Family as one or more of the Patents listed at Exhibit B; provided, however, that “Exhibit B Patents” does not
include any Patents listed in Exhibit A or Exhibit C. 
 1.8 “Exhibit C Patents” means (a) the Patents
listed at Exhibit C; and (b) any and all Patents that are part of the same Patent Family as one or more of the Patents listed at Exhibit C; provided, however, that “Exhibit C Patents” does not include any Patents listed
in Exhibit A or Exhibit B. 
 1.9 “Governmental Entity” means any court, administrative agency or commission or
other federal, state, county, local or foreign governmental authority, instrumentality, agency commission or subdivision thereof, including the U.S. Patent and Trademark Office (“PTO”) and the European Patent Office
(“EPO”). 
 1.10 “Inventor” means each of the named inventors of each of Patent. 

1.11 “Inventor Assignment Agreements” means each of Synecor’s fully executed agreements with each Inventor assigning to
Synecor all rights in the respective Patents. 
 1.12 “Next TransEnterix Cash/Liquidity Event” means the earliest date,
after the Effective Date, upon which (i) TransEnterix receives cumulative gross cash proceeds in an amount equal to or greater than $ 5, 000,000 (five million dollars) pursuant to (a) a sale of debt or equity securities, (b) a sale of
securities convertible into or exercisable for such debt or equity securities, (c) a sale or license of one or more of its assets (including, without limitation, its intellectual property, technology, or products), (d) a grant received
from any entity or organization, whether governmental or otherwise, or (e) any other transaction that results in the receipt of cash proceeds by TransEnterix, whether pursuant to one or more of the foregoing transactions and whether pursuant to
a single transaction or series of transactions; or (ii) TransEnterix is acquired by another entity by means of any transaction or series of related transactions including, without limitation, any stock acquisition, reorganization, merger or
consolidation, or a sale, lease, license or other disposition of all or substantially all of the assets of TransEnterix or any of its subsidiaries by means of any transaction or series of related transactions; or (iii) TransEnterix shareholders
receive cash proceeds in an amount equal to or greater than $5,000,000 (five million dollars) in a transaction in which TransEnterix is liquidated, dissolved or wound up, whether voluntarily or involuntarily. 

  
 -2- 

 1.13 “Patents” means any United States or foreign patents and applications
(including provisional applications), patents issuing from such applications, certificates of invention or any other grants by any Governmental Entity for the protection of inventions, and all reissues, renewals, continuations,
continuations-in-part, re-examinations and extensions of any of the foregoing; provided, however, that when the term “Patent” is used in the context of, or to refer to, a particular patent or patent application, or a patent or patent
application on a schedule, the term shall mean only that particular patent or patent application, as the case may be. 
 1.14 “Patent
Documents” means all (i) prosecution files and docketing reports for any of the Assigned Patents; (ii) Inventor Assignment Agreements; (iii) all documents, records and files in the possession or control of Synecor, its
counsel or its agents (and including any and all of each Inventor) with respect to (A) the conception or reduction to practice of the claims made in any of the Assigned Patents, (B) the acquisition, prosecution, registration, continuation,
continuation-in-part, reissuance, correction, enforcement, defense, and maintenance of the Assigned Patents, and (C) Synecor’s marking activities and program(s) with respect to the Assigned Patents, and (iv) any other material
documentation or information in the possession or control of Synecor, its counsel or its agents related to the Assigned Patents. 
 1.15
“Patent Family” means a set comprised of all Patents that are (a) linked through one or more claims of priority pursuant to 35 U.S.C. Sections 120 or 119(e) (the equivalent laws or regulation of any other patent authority)
or by a terminal disclaimer pursuant to 35 U.S.C. Sec. 253 or 37 CFR 1.321 (or the equivalent laws or regulation of any other patent authority) or (b) that are foreign counterparts, reissues, divisionals, renewals, extensions, continuations or
continuations-in-part with respect to any other Patent in such set. 
 1.16 “TransEnterix License” shall mean the License
Agreement dated December 31, 2007 between TransEnterix and Synecor. 
 1.17 “TransEnterix Services” shall mean the
services provided by Synecor to TransEnterix during the term beginning on or about April 1, 2005 and ending on the Effective Date. 

1.18 “TransEnterix Work Product” shall mean all documents, records, files, materials, and prototypes created or developed by
Synecor, solely or jointly with TransEnterix, in the performance of TransEnterix Services. TransEnterix Work Product includes, but is not limited to, Patent Documents for each of the Exhibit B Patents and each of the Exhibit C Patents.

 1.19 “Transfer Documents” means fully executed Patent transfer documents, in a form approved by Barosense (for the
Exhibit A Patents) and TransEnterix (for the Exhibit B Patents and the Exhibit C Patents) suitable for filing with the relevant Governmental Authority, in each jurisdiction where the Patents issue from or have been filed, as the case
may be, in each case to record the change of ownership of the Patents from Synecor to Barosense or TransEnterix as the case may be. 
 1.20
Construction. 
 1.20.1 As used in this Agreement, the words “include” and “including” and variations thereof will
not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.” 

  
 -3- 

 2. TERMINATION OF LICENSES 

2.1 Concurrently with the assignment of the Exhibit A Patents to Barosense, Barosense and Synecor hereby mutually terminate the Barosense
License effective as of the Effective Date. Notwithstanding any terms to the contrary in the Barosense License, all terms of the Barosense License including all license grants therein, shall have no force and effect as of the Effective Date, and
Barosense shall have no rights under or license to any intellectual property, including Patent Rights, owned by Synecor or TransEnterix. 

2.2 Concurrently with the assignment of the Exhibit B Patents and the Exhibit C Patents to TransEnterix, TransEnterix and Synecor
hereby mutually terminate the TransEnterix License effective as of the Effective Date. Notwithstanding any terms to the contrary in the TransEnterix License, all terms of the TransEnterix License, including all license grants therein, shall have no
force and effect as of the Effective Date, and TransEnterix shall have no rights under or license to any intellectual property, including Patent Rights, owned by Synecor or Barosense. 

3. ASSIGNMENT 
 3.1 Synecor hereby
irrevocably sells, transfers, conveys and assigns to Barosense, and Barosense shall acquire from Synecor all right, title and interest in and to (i) all Exhibit A Patents including, without limitation, causes of action and rights to
damages, payments, royalties and income for past, present or future infringements or misappropriations with respect thereto, in all countries relating to the Exhibit A Patents; (ii) the Patent Documents and rights (including copyrights)
with respect thereto; and (iii) the Barosense Work Product and all trade secrets, know-how and inventions described or shown therein. On the Effective Date, Synecor shall execute, have notarized and deliver the Transfer Documents in accordance
with Section 5.1. Barosense shall thereafter have sole responsibility and authority to prosecute any pending Patent application included in the Exhibit A Patents, and shall assume responsibility for all fees and expenses associated with
the Exhibit A Patents including, without limitation, all maintenance, annuity and prosecution-related fees and expenses. 
 3.2 Synecor
hereby irrevocably sells, transfers, conveys and assigns to TransEnterix, and TransEnterix shall acquire from Synecor all right, title and interest in and to (i) all Exhibit B Patents and all Exhibit C Patents including, without
limitation, causes of action and rights to damages, payments, royalties and income for past, present or future infringements or misappropriations with respect thereto, in all countries relating to the Exhibit B Patents and the Exhibit C
Patents; (ii) the Patent Documents and rights (including copyrights) with respect thereto; and (iii) the TransEnterix Work Product and all trade secrets, know-how and inventions described or shown therein. On the Effective Date, Synecor
shall execute, have notarized and deliver the Transfer Documents in accordance with Section 5.2. TransEnterix shall thereafter have sole responsibility and authority to prosecute any pending Patent application included in the Exhibit B
Patents and the Exhibit C Patents, and shall assume responsibility for all fees and expenses associated with the Exhibit B Patents and the Exhibit C Patents including, without limitation, all maintenance, annuity and
prosecution-related fees and expenses. 

  
 -4- 

 4. CONSIDERATION 

4.1 In partial consideration for the termination of the Barosense License by Barosense, TransEnterix shall pay or have paid to Barosense a
total sum of $ 5,000,000 (five million dollars) in two installments as follows: (i) the first installment shall be in the amount of $ 2,500,000 and shall be paid no later than three (3) days after the Effective Date; and (ii) the
second installment (the “Final Payment”) shall be in the amount of $ 2,500,000 and shall be paid no later than the earliest of the closing of the Next TransEnterix Cash/Liquidity Event and December 26, 2010. 

4.2 In the event the Final Payment is not made on or before December 26, 2010, TransEnterix may, at its option, extend the term for
payment of the Final Payment until the earlier of three (3) days after the closing of the Next TransEnterix Cash/Liquidity Event and December 26, 2011. TransEnterix shall notify Barosense of its intent to extend the term for payment of the
Final Payment by, on or before December 26, 2010, paying to Barosense the sum of $ 1,000,000 (one million dollars) (the “Option Payment”). 

4.3 Default. In the event (i) the Final Payment is not made by three (3) days after the closing of the Next TransEnterix
Cash/Liquidity Event and TransEnterix’ failure to make the Final Payment is not cured under Section 4.4, (ii) after payment of the Option Payment, the Final Payment is not made on or before the earlier of three (3) days after the
closing of the Next TransEnterix Cash/Liquidity Event and December 26, 2011 and TransEnterix’ failure to make the Final Payment is not cured under Section 4.4, (iii) neither the Final Payment nor the Option Payment is made on or
before December 26, 2010, or (iv) if , prior to December 26, 2010, TransEnterix is liquidated, dissolved or wound up in a manner which does not constitute a TransEnterix Cash/Liquidity Event, the Final Payment will be in default.
Ownership of the Assigned Patents and other rights assigned under Sections 3.1 and 3.2 shall thereafter revert to Synecor and the Barosense License and the TransEnterix License shall be reinstated as follows: 

(a) Ownership of the Exhibit A Patents, Exhibit B Patents, Exhibit C Patents, and trade secrets, know-how, and inventions
described or shown in the Barosense Work Product and the TransEnterix Work Product shall automatically revert to Synecor on the date of the default. Within thirty (30) days of the date of the default, Barosense and TransEnterix shall
(i) execute, have notarized and delivered to Synecor Transfer Documents pertaining to the Assignment to Synecor of the Exhibit A Patents (in the case of Barosense) and the Exhibit B Patents and Exhibit C Patents (in the case of
TransEnterix), and (ii) deliver the Patent Documents pertaining to the Assigned Patents and all Barosense Work Product and TransEnterix Work Product received pursuant to Sections 5.1(b) and 5.2(b) to Synecor. 

(b) Upon Barosense’s delivery to Synecor of the Transfer Documents, the Barosense Work Product received pursuant to Section 5.1(b),
and Patent Documents pertaining to the Exhibit A Patents, the Barosense License shall be automatically reinstated.(c) Upon TransEnterix’ delivery to Synecor of the Transfer Documents, the TransEnterix Work Product received pursuant to
Section 5.2(b) and Patent Documents pertaining to the Exhibit B Patents and the Exhibit C Patents, the TransEnterix License shall be automatically reinstated. 

  
 -5- 

 In the event that there has been a Next TransEnterix Cash/Liquidity Event and the Final Payment is in default
under Section 4.3, then the foregoing reinstatement of ownership is without limitation to Barosense’s other remedies for the default including the right to receive the Final Payment, which right shall continue notwithstanding the
reinstatement of ownership. 
 4.4 Cure. In the event TransEnterix fails to make the Final Payment by three (3) days after the
closing of the Next TransEnterix Cash/Liquidity Event, the Final Payment shall not be in default if TransEnterix makes the Final Payment, plus interest at a rate equal to the Prime Rate accruing from the date the Final Payment was originally due,
within seven (7) days after receiving written notice from Barosense. 
 5. DELIVERY 

5.1 Delivery to Barosense. Synecor shall have delivered to Barosense the following: 

(a) Within three (3) days of the Effective Date, all Transfer Documents pertaining to the Exhibit A Patents, fully executed; and 

(b) Within thirty (30) days of the Effective Date, the Patent Documents pertaining to the Exhibit A Patents and any Barosense Work
Product not previously delivered to Barosense. 
 5.2 Delivery to TransEnterix. Synecor shall have delivered to TransEnterix the
following: 
 (a) Within three (3) days of the Effective Date, all Transfer Documents pertaining to the Exhibit B Patents and the
Exhibit C Patents, fully executed; and 
 (b) Within thirty (30) days of the Effective date, the Patent Documents pertaining to the
Exhibit B Patents and the Exhibit C Patents and any TransEnterix Work Product not previously delivered to TransEnterix. 
 5.3
Form of Transfer Document for Patents. Synecor shall provide Transfer Documents for all Assigned Patents in the form provided in Exhibit D, without limiting the right to further papers or documents as needed pursuant to Section 6
(Further Assurances). 
 5.4 Privilege. In the event Synecor has a concern that loss of attorney-client privilege in a Patent Document
would result from a transfer of a Patent Document, Synecor shall consult with the respective Party to which the Patent Document is to be transferred and transfer the Patent Document in the manner directed by such Party. Subject to receiving such
instructions from the Party to receive the Patent Document, Synecor shall not have the right to withhold transfer of a Patent Document because of concerns regarding attorney-client privilege. 

6. FURTHER ASSURANCES 
 6.1 Further
Cooperation. Upon Barosense’s or TransEnterix’ request, with reasonable notice given, and without additional consideration, Synecor shall execute any further papers and documents and do such other acts as may be necessary and proper to
vest full title in and to the 

  
 -6- 

 
Exhibit A Patents in Barosense and Exhibit B Patents and Exhibit C Patents in TransEnterix. Synecor shall assist Barosense and TransEnterix, and any successor, in every proper way
to secure such Parties’ rights in the applicable Assigned Patents in any and all countries, including the execution of all applications, specifications, oaths, assignments and all other instruments which Barosense or TransEnterix shall
reasonably deem necessary in order to apply for and obtain such rights and in order to assign and convey to Barosense and TransEnterix, their successors, assigns, and nominees the sole and exclusive right, title and interest in and to the respective
Assigned Patents. 
 6.2 Limited Power of Attorney to Barosense. Synecor irrevocably constitutes and appoints Barosense, with full
power of substitution, to be its true and lawful attorney, and in its name, place or stead, to execute, acknowledge, swear to and file, all instruments, conveyances, certificates, agreements and other documents, and to take any action which shall be
necessary, appropriate or desirable to effectuate the transfer, or prosecution of the Exhibit A Patents in accordance with the terms of this Agreement; provided, however, that such power shall be exercised by Barosense only in the event that
Synecor fails to take the necessary actions required hereunder to affect or record such transfer, or prosecution of such Exhibit A Patents following Barosense’s reasonable request, and being given a reasonable opportunity to do so. This
power of attorney shall be deemed to be coupled with an interest and shall be irrevocable. 
 6.3 Limited Power of Attorney to
TransEnterix. Synecor irrevocably constitutes and appoints TransEnterix, with full power of substitution, to be its true and lawful attorney, and in its name, place or stead, to execute, acknowledge, swear to and file, all instruments,
conveyances, certificates, agreements and other documents, and to take any action which shall be necessary, appropriate or desirable to effectuate the transfer, or prosecution of the Exhibit B Patents and the Exhibit C Patents in
accordance with the terms of this Agreement; provided, however, that such power shall be exercised by TransEnterix only in the event that Synecor fails to take the necessary actions required hereunder to affect or record such transfer, or
prosecution of such Exhibit B Patents and Exhibit C Patents following TransEnterix’ reasonable request, and being given a reasonable opportunity to do so. This power of attorney shall be deemed to be coupled with an interest and shall
be irrevocable. 
 6.4 Additional Cooperation. In addition to Section 6.1 (Further Cooperation), Synecor shall, and Synecor shall
direct its employees (including all employed Inventors) to, fully cooperate with, including facilitating the cooperation of the Inventors (whether employed or not), and assist Barosense and TransEnterix, its counsel and similar agents in the
enforcement, prosecution and maintenance of the respective Assigned Patents assigned to such Party, in each case without additional consideration. 

6.5 Further Cooperation to Synecor. In the event of reversion of ownership of any of the Assigned Patents to Synecor in accordance with
Section 4.3, 7.2 or 7.3, upon Synecor’s request, with reasonable notice given, and without additional consideration, Barosense and/or TransEnterix shall execute any further papers and documents and do such other acts as may be necessary
and proper to vest full title in and to the Exhibit A Patents, Exhibit B Patents and Exhibit C Patents in Synecor. Barosense and TransEnterix shall assist Synecor, and any successor, in every proper way to secure Synecor’s rights
in the applicable Assigned Patents in any and all countries, including the execution 

  
 -7- 

 
of all applications, specifications, oaths, assignments and all other instruments which Synecor shall reasonably deem necessary in order to apply for and obtain such rights and in order to assign
and convey to Synecor, their successors, assigns, and nominees the sole and exclusive right, title and interest in and to the respective Assigned Patents. 

6.6 Limited Power of Attorney to Synecor. Each of TransEnterix and Barosense irrevocably constitute and appoint Synecor, with full power
of substitution, to be its true and lawful attorney, and in its name, place or stead, to execute, acknowledge, swear to and file, all instruments, conveyances, certificates, agreements and other documents, and to take any action which shall be
necessary, appropriate or desirable to effectuate the transfer, or prosecution of the Assigned Patents reverting to Synecor in accordance with the terms of Sections 4.3, 7.2 and 7.3 of this Agreement; provided, however, that such power shall be
exercised by Synecor only in the event that Barosense or TransEnterix fails to take the necessary actions required hereunder to affect or record such transfer, or prosecution of such Assigned Patents following Synecor’s reasonable request, and
being given a reasonable opportunity to do so. This power of attorney shall be deemed to be coupled with an interest and shall be irrevocable. 
 7.
WARRANTIES 
 7.1 Synecor represents and warrants to Barosense and to TransEnterix that: 

(a) As of the Effective Date, and prior to the transfer to Barosense and to TransEnterix hereunder, Synecor owns all right, title and interest
to the Assigned Patents, free and clear of any Encumbrances other than the license rights granted in the Barosense License and the TransEnterix License. Upon transfer of the Assigned Patents to Barosense and to TransEnterix hereunder, none of the
Assigned Patents will be subject to any restrictions with respect to the transfer or licensing of such Patents or is subject, or will be subject, to any Encumbrance as a result of any facts, circumstances or agreements existing before the Effective
Date. 
 (b) As of the Effective Date Synecor has not granted any license, waived any rights of enforcement (including but not limited to any
covenant not to sue), released any claim, or otherwise granted similar rights with respect to any of the Assigned Patents nor committed to, or taken any action that would commit Synecor to, license or grant any rights with respect to any of the
Assigned Patents other than the license rights granted in the Barosense License and the TransEnterix License. 
 (c) To Synecor’s
knowledge, Exhibit A sets forth a true and accurate list of the Exhibit A Patents, Exhibit B sets forth a true and accurate list of the Exhibit B Patents, and Exhibit C sets forth a true and accurate list of the
Exhibit C Patents, and for each of such Patent in such exhibits set forth the title, the Patent number or serial number (as applicable), the filing date or issue date, and the country in which the relevant Patent has been issued, or applied
for. No Exhibit A Patent is an Exhibit B Patent or an Exhibit C Patent, no Exhibit B Patent is an Exhibit A Patent or an Exhibit C Patent, and no Exhibit C Patent is an Exhibit A Patent or an Exhibit B
Patent. 

  
 -8- 

 (d) The Patent Documents to be delivered by Synecor hereunder, to Barosense in with respect to
the Exhibit A Patents and to TransEnterix with respect to the Exhibit B Patents and the Exhibit C Patents, represent all material records and files of Synecor, its counsel and agents of which Synecor is aware related to the Assigned
Patents, with respect to the acquisition, prosecution, registration, continuation, reissuance, enforcement, defense, and maintenance of the Assigned Patents, Synecor has not, to its knowledge, retained copies of any material Patent Document. 

(e) The Exhibit A Patents are the complete set of Patents known to Synecor that are or were owned or invented by Synecor or its Affiliates
(including jointly with any other person or entity) covering Barosense Work Product and no Exhibit B Patent and no Exhibit C Patent, to Synecor’s knowledge, covers Barosense Work Product. 

(f) The Exhibit B Patents and the Exhibit C Patents are the complete set of Patents known to Synecor that are or were owned or
invented by Synecor or its Affiliates (including jointly with any other person or entity) covering TransEnterix Work Product and no Exhibit A Patent, to Synecor’s knowledge, covers TransEnterix Work Product. 

(g) To Synecor’s knowledge, neither the execution, delivery or performance of this Agreement nor the consummation of the transactions
contemplated hereby will impair the right of Barosense or TransEnterix to use, possess, sell, license or dispose of any of the Exhibit A Patents (in the case of Barosense) or the Exhibit B Patents or the Exhibit C Patents (in the case
of TransEnterix) except in the event the reversions of ownership of Sections 4.3, 7.2 or 7.3 should take effect. There are no royalties, honoraria, fees or other payments payable by Synecor to any third party by reason of the ownership, use,
possession, license, sale, or disposition of any Assigned Patents. 
 (h) Synecor has disclosed or shall disclose to Barosense or
TransEnterix within thirty (30) days of the Effective Date through delivery of the Patent Documents all facts and circumstances known (but without requiring specific due diligence or inquiry by Synecor) to Synecor on or prior to the Effective
Date as having an adverse effect on the validity or enforceability of the Exhibit A Patents (any such information has been or shall be disclosed to Barosense) and the Exhibit B Patents and the Exhibit C patents (any such information
has been or shall be disclosed to TransEnterix). 
 (i) To Synecor’s knowledge, no Assigned Patents are subject to any proceeding or
outstanding decree, order, judgment, settlement agreement or stipulation. 
 (j) To Synecor’s knowledge, none of the Assigned Patents
were developed by or on behalf of or using grants of any Governmental Entity. 
 (k) There are no broker’s or finder’s fees to be
paid by Synecor, and Synecor has no knowledge of, and has taken no action which would give rise to, any claim for a broker’s or finder’s fee to be paid by Barosense or TransEnterix in connection with the consummation of the transactions
provided for in this Agreement. 
 (l) Synecor is a corporation duly organized, validly existing and in good standing under the respective
laws of its jurisdiction of incorporation, is duly qualified and is in good standing under the laws of each jurisdiction in which the character of the properties and assets now owned or held by it or the nature of the business now conducted by it
requires it to be so licensed or qualified. Synecor has full corporate power and authority to carry on its business as now being conducted. 

  
 -9- 

 (m) Synecor has full corporate power and authority to execute and deliver this Agreement and to
perform its obligations hereunder. The execution and delivery of this Agreement by Synecor and the performance by Synecor of its obligations hereunder have been duly authorized by all necessary corporate action. This Agreement has been duly executed
and delivered by Synecor and constitutes the legal, valid and binding obligation of Synecor, enforceable against it in accordance with its terms, subject to applicable laws affecting creditors’ rights generally and, as to enforcement, to
general principles of equity, regardless of whether applied in a proceeding at law or in equity. 
 (n) To Synecor’s knowledge, the
execution and delivery of this Agreement and the performance of the obligations of Synecor hereunder will not (i) violate or be in conflict with any provision of law, any order, rule or regulation of any court or other agency of government, or
any provision of Synecor’s articles of incorporation or bylaws, or (ii) violate, be in conflict with, result in a breach of, constitute (with or without notice or lapse of time or both) a default under, or result in the acceleration of any
obligations under, any indenture, agreement, lease or other instrument to which Synecor is a party or by which it or any of its properties are bound. No consent, approval or authorization of or declaration or filing with any Governmental Entity or
other person or entity on the part of Synecor is required in connection with the execution or delivery of this Agreement or the consummation of the transactions contemplated hereby. 

(o) Synecor, to its knowledge, (i) will not be insolvent as of the Effective Date and will not become insolvent as a result of the
transactions contemplated herein, (ii) is not engaged in a business or transaction, or about to engage in a business or a transaction, for which any property remaining with Synecor after giving effect to the transactions contemplated herein is
or will be unreasonably small capital, (iii) does not intend to incur, and does not believe that it will incur, debts that would be beyond Synecor’s ability to pay as they mature, and (iv) as of the Effective Date will generally be
paying its obligations as they come due. For purposes hereof, the term “insolvent” shall have the meaning given to it in 11 U.S.C. § 101(32). 

(p) Synecor is not entering into the transactions contemplated herein with the actual intent to hinder, delay or defraud any entity to which
Synecor is or will become, on or after the Effective Date, indebted. 
 (q) To Synecor’s knowledge, the transactions and agreements
contained herein do not violate any state or federal fraudulent transfer, fraudulent conveyance or bulk sale laws, or any other laws of similar effect. 

(r) None of the representations or warranties made by Synecor herein or in any of the Schedules or in any Transfer Document or Release Document
furnished by or on behalf of Synecor pursuant to this Agreement, when all such documents are read together in their entirety, are known by Synecor to contain any untrue statement of material fact, or omit to state any material fact necessary in
order to make the statements contained herein or therein, in the light of the circumstances under which made, not misleading. 

  
 -10- 

 7.2 Barosense represents and warrants that as of the Effective Date it has not granted any
sublicense or right to the Exhibit B Patents or the Exhibit C Patents or to any rights under the Barosense License other than to the Exhibit A Patents or the Barosense Work Product, or taken any action that would commit Barosense to
grant any sublicense or right to the Exhibit B Patents or the Exhibit C Patents or to any rights under the Barosense License other than the Exhibit A Patents or the Barosense Work Product. In the event of a breach of the
representations and warranties of this Section 7.2, the remedy for such breach shall include automatic reversion to Synecor of ownership of the Exhibit A Patents and trade secrets, know-how and inventions described or shown in the
Barosense Work Product. Barosense shall immediately thereafter (i) refund to TransEnterix all consideration paid to Barosense under Section 4 and forfeit any consideration to be paid under Section 4, (ii) execute, have notarized
and delivered to Synecor Transfer Documents pertaining to the re-assignment to Synecor of the Exhibit A Patents, and (iii) deliver the Patent Documents pertaining to the Exhibit A Patents and the Barosense Work Product received
pursuant to Section 5.1(b) to Synecor. Upon Barosense’s delivery to Synecor of all such Transfer Documents, Patent Documents and Barosense Work Product , the Barosense License shall be automatically reinstated, provided however, that
notwithstanding anything to the contrary in the Barosense License, the license grant to Barosense under the reinstated Barosense License shall not include rights under the Exhibit B Patents, the Exhibit C Patents or the trade secrets,
know-how and inventions described or shown in the TransEnterix Work Product. 
 7.3 TransEnterix represents and warrants that as of the
Effective Date it has not granted any sublicense or right to the Exhibit A Patents or to any rights under the TransEnterix License other than the Exhibit B Patents, the Exhibit C Patents or the TransEnterix Work Product, or taken any
action that would commit TransEnterix to grant any sublicense or right to the Exhibit A Patents or to any rights under the TransEnterix License other than the Exhibit B Patents or the Exhibit C Patents or the TransEnterix Work
Product. In the event of a breach of the representations and warranties of this Section 7.3, the remedy for such breach shall include automatic reversion to Synecor of ownership of the Exhibit B Patents and the Exhibit C Patents and
the trade secrets, know-how and inventions described or shown in the TransEnterix Work Product. TransEnterix shall immediately thereafter (i) execute, and have notarized and delivered to Synecor Transfer Documents pertaining to the
re-assignment to Synecor of the Exhibit B Patents and the Exhibit C Patents, and (ii) deliver the Patent Documents pertaining to the Exhibit B Patents and the Exhibit C Patents and the TransEnterix Work Product received
pursuant to Section 5.2(b) to Synecor. Upon TransEnterix’ delivery to Synecor of all such Transfer Documents, Patent Documents, and TransEnterix Work Product, the TransEnterix License shall be automatically reinstated, provided
however, that notwithstanding anything to the contrary in the TransEnterix License, the license grant to TransEnterix under the reinstated TransEnterix License shall not include rights under the Exhibit A Patents or the trade secrets, know-how
or inventions described or shown in the Barosense Work Product. 
 7.4 Except for the warranties explicitly set forth in Sections 7.1 through
7.3 of this agreement, Synecor, Barosense and TransEnterix do not make any representations or warranties of any kind, whether oral or written, whether express, implied, or arising by statute custom, course of dealing or trade usage, with respect to
the Assigned Patents or in connection with this Agreement. The Parties specifically disclaim any and all implied warranties or conditions of merchantability, fitness for a particular purpose, validity of the Assigned Patents, and non-infringement of
third party intellectual property rights. 

  
 -11- 

 8. NO IMPLIED RIGHTS 

8.1 Except as set forth in Section 3, nothing in this Agreement shall be construed as conferring to any Party by implication, estoppel, or
otherwise any Patent Rights or rights to any intellectual property of any other Party. Barosense acknowledges that it has no license or right under the Exhibit C Patents. 

9. GENERAL 
 9.1 Entire Agreement.
This Agreement sets forth the entire agreement and understanding between the Parties as to the subject matter hereof and supersedes all prior agreements and understandings, both written and oral, among and between any of the Parties with respect to
the subject matter hereof. 
 9.2 Governing Law and Jurisdiction. This Agreement shall be interpreted and construed in accordance with
the laws of the State of California, without regard to its conflict of law principles. Each of the Parties irrevocably consents to the exclusive jurisdiction and venue of any state court located within Santa Clara County, State of California in
connection with any matter based upon or arising out of this Agreement or the transactions contemplated hereby, agrees that process may be served upon them in any manner authorized by the laws of the State of California for such persons and waives
and covenants not to assert or plead any objection which they might otherwise have to such jurisdiction, venue and process. Each Party hereby agrees not to commence any legal proceedings relating to or arising out of this Agreement or the
transactions contemplated hereby in any jurisdiction or courts other than as provided herein. 
 9.3 Confidentiality. Each Party
agrees that the terms and conditions, but not the existence, of this Agreement shall be treated as the other’s confidential information and that no reference to the terms and conditions of this Agreement or to activities pertaining thereto may
be made in any form of public or commercial advertising without the prior written consent of the other Party; provided, however, that each Party may disclose the terms and conditions of this Agreement: (i) as required by any Governmental
Entity; (ii) as otherwise required by law; (iii) in confidence to legal counsel of the Parties; (iv) in connection with the requirements of a public offering or securities filing; (v) in confidence, to accountants, rating
agencies, banks, and financing sources and their advisors; (vi) in confidence, in connection with the enforcement of this Agreement or rights under this Agreement; or (vii) as required or advisable in a filing with a Governmental Entity to
perfect a Party’s rights in its Assigned Patents . On the Effective Date, any and all confidential information of Synecor with respect to the Assigned Patents and work product, including the Patent Documents, shall be deemed confidential
information of Barosense (in the case of the Exhibit A Patents and the Barosense Work Product) and of TransEnterix (in the case of the Exhibit B Patents and the Exhibit C Patents and the TransEnterix Work Product) and shall not be
used or disclosed to third parties by Synecor for any purpose whatsoever. If a Party is required to disclose this Agreement or the terms hereof pursuant to a subpoena or other legal mandate, it shall immediately give the other Parties notice thereof
and cooperate with such other Parties in contesting or limiting such subpoena or legal mandate. 

  
 -12- 

 9.4 Notices. All notices and other communications hereunder shall be in writing and shall
be deemed given if delivered personally or by commercial messenger or courier service, or mailed by registered or certified mail (return receipt requested) or sent via facsimile (with acknowledgment of complete transmission) to the Parties at the
following addresses (or at such other address for a Party as shall be specified by like notice); provided, however, that notices sent by mail will not be deemed given until received: 

If to Synecor, to: 
 Synecor LLC

 3908 Patriot Drive, Suite 170 

Durham, North Carolina 27703 

Attention: President 
 Telephone
No.: (919) 541-9977 
 Facsimile No.: (919) 541-9978 

If to Barosense, to: 
 Barosense,
Inc. 
 3698-C Haven Avenue 

Redwood City, CA 94063 

Attention: CEO 
 Telephone No.:
(650) 362-6000 
 Facsimile No.: (650) 362-0070 

If to TransEnterix, to: 

TransEnterix, Inc. 
 3908 Patriot
Drive, Suite 170 
 Durham, North Carolina 27703 

Attention: CEO 
 Telephone No.:
(919) 541-9977 
 Facsimile No.: (919) 541-9978 

Neither Party may commence any action against the other Party hereunder in any court, through arbitration, or other forum, without giving such
Party at least fifteen (15) days’ notice prior thereto, except where a longer period is expressly provided hereunder. 
 9.5
Assignment. The terms and conditions of this Agreement will inure to the benefit of, and be binding upon, the respective successors and assigns of the Parties. 

9.6 Term. This Agreement will become effective on the Effective Date and shall continue in full force and effect in accordance with its
terms until the expiration of the last Patent that is subject to this Agreement except for the provisions of Section 6 (Further Assurances) which shall survive for a further six (6) years from such date. 

  
 -13- 

 9.7 Expenses. Each Party hereto shall pay its own expenses incident to this Agreement and
the transactions contemplated herein provided that the Party purchasing the respective Assigned Patents shall be responsible for costs associated with the filing or recording of any of the Transfer Documents with the PTO, EPO and any other similar
foreign Governmental Entity. 
 9.8 Severability. If any part, form or provision of this Agreement shall be held unenforceable, void
or illegal, the validity of the remaining portions or provisions shall not be affected thereby. 
 9.9 Counterparts. This Agreement
may be executed in one or more counterparts. 
 [signature page follows] 

  
 -14- 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized respective officers as of the date first written above. 
  

			
	SYNECOR LLC
		
	By:	 	 /s/ Richard S. Stack

		 	Richard S. Stack, MD, President
	
	BAROSENSE, INC.
		
	By:	 	 /s/ Daniel J. Balbierz

		 	Daniel J. Balbierz, President and CEO
	
	TRANSENTERIX, INC.
		
	By:	 	 /s/ R. Frederick McCoy, Jr.

		 	R. Frederick McCoy, Jr., Chairman of the Board

 EXHIBIT A 
  

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	BARO 200	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 09/940,110
 U.S. 6,675,809 (Issued
Jan 13, 2004) August 27, 2001

			
	BARO 200PCT	  	SATIATION DEVICES AND METHODS	  	 PCT/US02/27177
 August 26, 2002

			
	BARO 200JPN	  	SATIATION DEVICES AND METHODS	  	 Japanese 2003-522406
 August 26,
2002

			
	BARO 200CHN	  	SATIATION DEVICES AND METHODS	  	 Chinese Granted 02821217.7
 August 26, 2002
(Issued Apr 4, 2007 as ZL02821217.7)

			
	BARO 200EPC	  	SATIATION DEVICES AND METHODS	  	 European 02757395.5
 August 26,
2002

			
	BARO 210	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/118,289
 U.S. 6,845,776 (Issued
Jan 25, 2005) April 8, 2002

			
	BARO 210PCT	  	SATIATION DEVICES AND METHODS	  	 PCT/US03/04378
 February 13, 2003

			
	BARO 210CHN	  	SATIATION DEVICES AND METHODS	  	 Chinese 03812874.8
 February 13,
2003

			
	BARO 210EPC	  	SATIATION DEVICES AND METHODS	  	 European 03713446.7
 February 13,
2003

			
	BARO 210JPN	  	SATIATION DEVICES AND METHODS	  	 Japanese 2003-583273
 February 13,
2003

			
	BARO 211	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/751,751
 January 5,
2004

			
	BARO 212	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/794,007
 U.S. 7,152,607 (Issued
Dec 26, 2006) March 4, 2004

			
	BARO 213	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 11/958,587
 December 18,
2007

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	BARO 220	  	SATIATION DEVICE AND METHODS	  	 U.S. Provisional 60/379,306
 May 10,
2002

			
	BARO 230	  	SATIATION DEVICE AND METHODS	  	 U.S. Utility 10/345,914
 January 16,
2003

			
	BARO 230PCT	  	SATIATION DEVICES AND METHODS	  	 PCT/US03/04449
 February 13, 2003

			
	BARO 230CHN	  	SATIATION DEVICES AND METHODS	  	 Chinese 03813244.3
 February 13,
2003

			
	BARO 230EPC	  	SATIATION DEVICES AND METHODS	  	 European 03709101.4
 February 13,
2003

			
	BARO 230JPN	  	SATIATION DEVICES AND METHODS	  	 Japanese 2003-583274
 February 13,
2003

			
	BARO 240	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/457,108
 U.S. 7,111,627 (Issued
Sep 26, 2006) June 9, 2003

			
	BARO 241	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/794,346
 U.S. 7,121,283 (Issued
Oct 17 2006) March 4, 2004

			
	BARO 242	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/892,973
 U.S. 7,354,454 (Issued
Apr 8, 2008) July 16, 2004

			
	BARO 243	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 12/099,290
 April 8,
2008

			
	BARO 250	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/457,137
 June 9,
2003

			
	BARO 260	  	SATIATION DEVICES AND METHODS	  	 U.S. Utility 10/457,144
 June 9,
2003

			
	BARO 300	  	SATIATION POUCHES AND METHODS OF USE	  	 U.S. Utility 10/345,666
 January 16,
2003

			
	BARO 310	  	SATIATION POUCHES AND METHODS OF USE	  	 U.S. Utility 12/398,917
 March 5,
2009

			
	BARO 300PCT	  	SATIATION POUCHES AND METHODS OF USE	  	 PCT/US03/33605
 October 24,
2003

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	BARO 300EPC	  	SATIATION POUCHES AND METHODS OF USE	  	 European 03777817.2
 October 24,
2003

			
	BARO 300JPN	  	SATIATION POUCHES AND METHODS OF USE	  	 Japanese 2004-566913
 October 24,
2003

			
	BARO 400	  	POSITIONING TOOLS AND METHODS FOR IMPLANTING MEDICAL DEVICES	  	 U.S. Utility 10/345,698
 U.S. 7,097,665 (Issued
Aug 29, 2006) January 16, 2003

			
	BARO 400PCT	  	POSITIONING TOOLS AND METHODS FOR IMPLANTING MEDICAL DEVICES	  	 PCT/US03/33606
 October 24, 2003

			
	BARO 400EPC	  	POSITIONING TOOLS AND METHODS FOR IMPLANTING MEDICAL DEVICES	  	 European 03777818.0
 October 24,
2003

			
	BARO 400JPN	  	POSITIONING TOOLS AND METHODS FOR IMPLANTING MEDICAL DEVICES	  	 Japanese 2004-566914
 October 24,
2003

			
	BARO 410	  	POSITIONING TOOLS AND METHODS FOR IMPLANTING MEDICAL DEVICES	  	 U.S. Utility 11/479,204
 June 30,
2006

			
	BARO 500	  	ARTICULATED SUTURING DEVICE	  	 U.S. Utility 10/387,157
 March 12,
2003

			
	BARO 600	  	METHOD AND APPARATUS FOR MODIFYING THE EXIT ORIFICE OF A SATIATION POUCH	  	 U.S. Utility 10/387,031
 U.S. 7,146,984 (Issued
Dec 12, 2006) March 12, 2003

			
	BARO 600PCT	  	METHOD AND APPARATUS FOR MODIFYING THE EXIT ORIFICE OF A SATIATION POUCH	  	 PCT/US04/06695
 March 4, 2004

			
	BARO 600EPC	  	METHOD AND APPARATUS FOR MODIFYING THE EXIT ORIFICE OF A SATIATION POUCH	  	 European 04717435.4
 March 4, 2004

			
	BARO 600JPN	  	METHOD AND APPARATUS FOR MODIFYING THE EXIT ORIFICE OF A SATIATION POUCH	  	 Japanese 2006-509148
 March 4,
2004

			
	BARO 610	  	METHOD AND APPARATUS FOR MODIFYING THE EXIT ORIFICE OF A SATIATION POUCH	  	 U.S. Utility 11/195,204
 August 2,
2005

			
	BARO 700	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 U.S. Provisional 60/510,268
 October 10,
2003

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	BARO 701	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 U.S. Utility 10/843,702
 May 11,
2004

			
	BARO 710	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 U.S. Utility 10/898,036
 U.S. 7,431,725 (Issued
Oct 7, 2008) July 23, 2004

			
	BARO 711	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 U.S. Utility 11/512,975
 August 30,
2006

			
	BARO 720PCT	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 PCT/US04/33007
 October 8, 2004

			
	BARO 720	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 U.S. Utility 10/575,222
 April 10,
2006

			
	BARO 720EPC	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 European 04794380.8
 October 8,
2004

			
	BARO 720JPN	  	DEVICES AND METHODS FOR RETAINING A GASTRO- ESOPHAGEAL IMPLANT	  	 Japanese 2006-534310
 October 8,
2004

			
	BARO 800	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT FOR INDUCING WEIGHT LOSS	  	 U.S. Provisional 60/565,378
 April 26,
2004

			
	BARO 810	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT FOR INDUCING WEIGHT LOSS	  	 U.S. Utility 11/114,400
 April 26,
2005

			
	BARO 810PCT	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT FOR INDUCING WEIGHT LOSS	  	 PCT/US05/14372
 April 26, 2005

			
	BARO 810EPC	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT FOR INDUCING WEIGHT LOSS	  	 European 05744737.7
 April 26,
2005

			
	BARO 900	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT SYSTEM FOR INDUCING WEIGHT LOSS	  	 U.S. Provisional 60/683,635
 May 23,
2005

			
	BARO 910	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT SYSTEM FOR INDUCING WEIGHT LOSS	  	 U.S. Utility 11/439,461
 May 23,
2006

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	BARO 910PCT	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT SYSTEM FOR INDUCING WEIGHT LOSS	  	 PCT/US2006/019727
 May 23,
2006

			
	BARO 910EPC	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT SYSTEM FOR INDUCING WEIGHT LOSS	  	 European 06770834.7
 May 23,2006

			
	BARO 910JPN	  	RESTRICTIVE AND/OR OBSTRUCTIVE IMPLANT SYSTEM FOR INDUCING WEIGHT LOSS	  	 Japanese 2008-513585
 May 23, 2006

			
	SYNC 3300	  	POST PYLORIC SLEEVE	  	 U.S. Provisional 60/824,435
 September 2,
2006

			
	SYNC 3310	  	INTESTINAL SLEEVES AND ASSOCIATED DEPLOYMENT SYSTEMS AND METHODS	  	 U.S. Utility 11/897,701
 August 31,
2007

			
	SYNC3310PCT	  	INTESTINAL SLEEVES AND ASSOCIATED DEPLOYMENT SYSTEMS AND METHODS	  	 PCT/US2007/19227
 August 31, 2007

			
	SYNC3310EPC	  	INTESTINAL SLEEVES AND ASSOCIATED DEPLOYMENT SYSTEMS AND METHODS	  	 European 07837649.8
 August
31,2007

			
	SYNC3310JP	  	INTESTINAL SLEEVES AND ASSOCIATED DEPLOYMENT SYSTEMS AND METHODS	  	 Japanese
 Not yet assigned, based on

PCT/US2007/19227
 August 31, 2007

			
	BARO 1500	  	SYSTEM AND METHOD FOR ANCHORING STOMACH IMPLANT	  	 U.S. Provisional 60/844,823
 September 15,
2006

			
	BARO1510	  	SYSTEM AND METHOD FOR ANCHORING STOMACH IMPLANT	  	 U.S. Utility 11/901,023
 September 14,
2007

			
	BARO1510PCT	  	SYSTEM AND METHOD FOR ANCHORING STOMACH IMPLANT	  	 PCT/US2007/019940
 September 14,
2007

			
	BARO1510EPC	  	SYSTEM AND METHOD FOR ANCHORING STOMACH IMPLANT	  	 European 07811769.4
 September 14,
2007

 EXHIBIT B 
  

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	TRX-100A (formerly SYNC 3000)	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 U.S. Provisional 60/720,943
 Sept 27,
2005

			
	TRX-100	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 U.S. Provisional 60/760,132
 Jan 19,
2006

			
	TRX-110	  	PROCEDURAL CANNULA FOR TRANSGASTRIC SURGICAL PROCEDURES	  	 U.S. Utility 11/655,445
 January 19,
2007

			
	TRX-200	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATUAL ORIFICE ACCESS	  	 U.S. Provisional 60/794,563
 Apr. 24,
2006

			
	TRX-210	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATURAL ORIFICE ACCESS	  	 U.S. Utility 11/789,381
 April 24,
2007

			
	TRX-210PCT	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATURAL ORIFICE ACCESS	  	 PCT/US07/009936
 April 24, 2007.

			
	TRX-210AUS	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATURAL ORIFICE ACCESS	  	 Australian 2007000243484
 April 24,
2007

			
	TRX-210CAN	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATURAL ORIFICE ACCESS	  	 Canadian 2,650,474
 April 24, 2007

			
	TRX-210EPC	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATURAL ORIFICE ACCESS	  	 European 07755964.9
 April 24,
2007

			
	TRX-210JPN	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATURAL ORIFICE ACCESS	  	 Japanese 2009-507760
 April 24,
2007

			
	TRX-300	  	PROCEDURAL CANNULA AND SUPPORT SYSTEM FOR SURGICAL PROCEDURES USING NATUAL ORIFICE ACCESS	  	 U.S. Provisional 60/801,113
 May 17,
2006

			
	TRX-400	  	SYSTEM AND METHOD FOR SINGLE PORT SURGICAL ACCESS	  	 U.S. Provisional 60/801,034
 May 17,
2006

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	TRX-500	  	SYSTEMS AND METHODS FOR RESTORING FUNCTION OF DISEASED BOWEL	  	 U.S. Provisional No. 60/818,765
 July 6,
2006

			
	TRX-510	  	SYSTEMS AND METHODS FOR RESTORING FUNCTION OF DISEASED BOWEL	  	 U.S. Utility 11/825,464
 July 6,
2007

			
	TRX-510PCT	  	SYSTEMS AND METHODS FOR RESTORING FUNCTION OF DISEASED BOWEL	  	 PCT/US07/15526
 July 6, 2007

			
	TRX-600	  	CLOSURE DEVICES AND METHODS FOR NATURAL ORIFICE PROCEDURES	  	 U.S. Provisional 60/826,535
 September 21,
2006

			
	TRX-610	  	CLOSURE DEVICES AND METHODS FOR NATURAL ORIFICE PROCEDURES	  	 U.S. Utility 11/903,340
 Sept 21,
2007

			
	TRX-610PCT	  	CLOSURE DEVICES AND METHODS FOR NATURAL ORIFICE PROCEDURES	  	 PCT/US07/20440
 Sept 21, 2007

			
	TRX-610EPC	  	CLOSURE DEVICES AND METHODS FOR NATURAL ORIFICE PROCEDURES	  	 European 07838610.9
 Sept 21, 2007

			
	TRX-610JPN	  	CLOSURE DEVICES AND METHODS FOR NATURAL ORIFICE PROCEDURES	  	 Japanese - Not yet available (based on PCT/US07/20440)

Sept 21, 2007

			
	TRX-900	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT	  	 U.S. Provisional No. 60/819,235
 July 7,
2006

			
	TRX-910	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT	  	 U.S. Utility 11/804,063
 May 17,
2007

			
	TRX-910PCT	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT	  	 PCT/US07/011795
 May 17, 2007

			
	TRX-910AUS	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT	  	 Australian 2007254247
 May 17,
2007

			
	TRX-910CAN	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT	  	 Canadian 2,652,548
 May 17,
2007

					
	 Reference No.
	  	 Title
	  	 Serial No./Filing Date

	TRX-910EPC	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT.	  	 European 07794964.2
 May 17,
2007

			
	TRX-910JPN	  	SYSTEM AND METHOD FOR MULTI-INSTRUMENT SURGICAL ACCESS USING A SINGLE ACCESS PORT.	  	 Japanese 2009-511061
 May 17, 2007

			
	TRX-1000	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 U.S. Utility 11/528,009
 Sept 27,
2006

			
	TRX-1000PCT	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 PCT/US06/037978
 Sept 27, 2006

			
	TRX-1000AUS	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 Australian 2006294523
 Sept 27,
2006

			
	TRX-1000CAN	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 Canadian 2623948
 Sept 27, 2006

			
	TRX-1000JPN	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 Japanese 2008-533631
 Sept 27,
2006

			
	TRX-1000EPC	  	TRANSGASTRIC SURGICAL DEVICES AND PROCEDURES	  	 European 06825230.3
 Sept 27, 2006

  
 -3- 

 EXHIBIT C 
  

					
	 Reference No.
	  	 Title
	  	 Serial No. Filing Date

	TRX-1100	  	ARTICULATING ACCESS CANNULA	  	 U.S. Provisional No. 60/971,900
 Sept 12,
2007

			
	TRX-1110	  	DEVICES AND SYSTEMS FOR MINIMALLY INVASIVE SURGICAL PROCEDURES	  	 U.S. Utility 12/209,586
 Sept 12,
2008

			
	TRX- 1110PCT	  	DEVICES AND SYSTEMS FOR MINIMALLY INVASIVE SURGICAL PROCEDURES	  	 PCT/US08/10640
 Sept 12, 2008

			
	TRX-1120	  	SURGICAL SNARE WITH ELECTROSURGICAL TIP AND METHOD OF USE	  	 U.S. Utility 12/469,071
 May 20,
2009

			
	TRX-1200	  	SINGLE PORT ACCESS SYSTEM	  	 U.S. Provisional 60/971,903
 Sept 12,
2007

			
	TRX-1300	  	MULTI-LUMEN CANNULA	  	 U.S. Provisional 60/971,905
 Sept 12,
2008

			
	TRX- 1310PCT	  	MULTI-LUMEN CANNULA	  	 PCT/US08/76260
 Sept 12, 2008

			
	TRX-1700	  	MULTI-INSTRUMENT ACCESS DEVICES AND SYSTEMS	  	 U.S. Utility 12/209,408
 Sept 12,
2008

			
	TRX-	  	MULTI-INSTRUMENT ACCESS DEVICES AND SYSTEMS	  	CIP of TRX-1700 - under preparation.
			
	TRX- 1700PCT	  	MULTI-INSTRUMENT ACCESS DEVICES AND SYSTEMS	  	 PCT/US08/10663
 Sept 12, 2008

			
	9362-8PR	  	SATIATION DEVICES AND METHODS FOR CONTROLLING OBESITY	  	 U.S. Provisional No. 60/ 958,122
 July 3,
2007

			
	9362-8	  	SATIATION DEVICES AND METHODS FOR CONTROLLING OBESITY	  	 U.S. Utility 12/144,970
 June 24, 2008

 
 Published January 8, 2009 as US
2009-0012542

					
	 Reference No.
	  	 Title
	  	 Serial No. Filing Date

	9362-8WO	  	SATIATION DEVICES AND METHODS FOR CONTROLLING OBESITY	  	 PCT/US08/007825
 June 24,
2008

			
	9362-9PR	  	DEVICES FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE AND HIATAL HERNIA, AND METHODS OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND HIATAL HERNIA USING SAME	  	 U.S. Provisional No. 60/958,303
 July 3,
2007

			
	9362-9	  	DEVICES FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE AND HIATAL HERNIA, AND METHODS OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND HIATAL HERNIA USING SAME	  	 U.S. Utility 12/144,990
 June 24, 2008

 
 Published January 8, 2009 as US 2009-0012546.

			
	9362-9WO	  	DEVICES FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE AND HIATAL HERNIA, AND METHODS OF TREATING GASTROESOPHAGEAL REFLUX DISEASE AND HIATAL HERNIA USING SAME	  	 PCT/US08/007846
 June 24, 2008

 EXHIBIT D 

PATENT ASSIGNMENT 

WHEREAS, Synecor LLC, a Delaware limited liability company (hereinafter “Assignor”), owns the patent registrations and
applications listed and described on Schedule A attached hereto (the “Patents”); and 
 WHEREAS, SELLER and
BUYER, a             corporation (“Assignee”), have entered into a Patent Acquisition and License Termination Agreement dated     , 2009 (the
“Agreement”), pursuant to which Assignor has agreed, inter alia, to grant to Assignee all of Assignor’s right title and interest in and to the Patents and Assignee desires to acquire the entire right, title and interest in and
to the Patents. 
 NOW, THEREFORE, for and in consideration of the sum of One Dollar ($1.00) and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged: 
 1. Assignor hereby irrevocably sells, transfers, conveys and
assigns to Assignee, and Assignee shall acquire from Assignor all right, title and interest in and to all Patents including, without limitation, (a) all foreign counterparts, reissues, divisionals, renewals, extensions, continuations thereof
and (b) causes of action and rights to damages, payments, royalties and income for past, present or future infringements or misappropriations with respect thereto, in all countries relating to the Patents. 

2. Upon Assignee’s request, with reasonable notice given, and without additional consideration, Assignor shall execute any further papers
and documents and do such other acts as may be necessary and proper to vest full title in and to the Patents in Assignee. Assignor shall assist Assignee, and any successor, in every proper way to secure Assignee’s rights in the Patents in any
and all countries, including the execution of all applications, specifications, oaths, assignments and all other instruments which Assignee shall reasonably deem necessary in order to apply for and obtain such rights and in order to assign and
convey to Assignee, its successors, assigns, and nominees the sole and exclusive right, title and interest in and to the Patents. 
 3.
Assignor irrevocably constitutes and appoints Assignee, with full power of substitution, to be its true and lawful attorney, and in its name, place or stead, to execute, acknowledge, swear to and file, all instruments, conveyances, certificates,
agreements and other documents, and to take any action which shall be necessary, appropriate or desirable to effectuate the transfer, or prosecution of the Patents in accordance with the terms of this Agreement; provided, however, that such power
shall be exercised by Assignee only in the event that Assignor fails to take the necessary actions required hereunder to affect or record such transfer, or prosecution of the Patents following Assignee’s reasonable request, and being given a
reasonable opportunity to do so. This power of attorney shall be deemed to be coupled with an interest and shall be irrevocable. 

 4. Assignor also hereby authorizes the Commissioner of Patents to issue any and all Letters
Patent which may be granted upon the Patents herein referenced to Assignee, as the assignee to the entire interest therein. 
 IN WITNESS
WHEREOF, this Patent Assignment is executed at             as of this             day of
            . 
  

	
	 SELLER

	
	
By:                        
                                         
                         

	
	
Name:                        
                                         
                   

	
	
Title:                        
                                         
                      

 ACKNOWLEDGMENT 

 

			
	State of             	  	)
		  	) ss:
	County of             	  	)

  
 On this
            day of             , before me, the undersigned, personally appeared
            , personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed this instrument on behalf of the corporation named herein, and
acknowledged that s/he executed it in such representative capacity. 
 IN WITNESS WHEREOF, I have hereunto set my hand and official
seal. 
  

	
	  
 Notary Public

  

	
	My Commission Expires onEX-10.5

 Exhibit 10.5 

DEVELOPMENT AND SUPPLY AGREEMENT 

This Development and Supply Agreement (“Agreement”) is made as of this 4th day of November, 2011 (“Effective
Date”), by and between Microline Surgical, Inc. of 800 Cummings Center, Suite 166T, Beverly, MA 01915 (“Microline”) and Transenterix, Inc. of 635 Davis Drive, Suite 300, Durham, North Carolina 27713
(“Transenterix”). 
 WHEREAS, Microline develops and sells flexible and rigid sealing instruments for use in surgical
procedures; 
 WHEREAS, Transenterix has developed and launched the Spider System (as defined below), and wishes to engage Microline to
develop the FVS Product (as defined below) for exclusive use in the Field with the Spider System; and 
 WHEREAS, following the development
of such FVS Product, Microline shall supply such FVS Product, along with the UPS Product (as defined below), to Transenterix on the terms and conditions set forth herein; 

NOW THEREFORE in consideration of the foregoing premises and for good and valuable consideration (the receipt and sufficiency of which is
hereby acknowledged by the parties), the parties hereby agree as follows: 
 1. DEFINITIONS 

(a) “Affiliates” shall mean a person or entity that directly, or indirectly through one or more intermediaries, controls or is
controlled by, or is under common control with, the person specified. For purposes of this definition, the terms “control,” “controlled by” and “under common control with” shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the management or policies of such person and, in the case of an entity, shall require (a) in the case of a corporate entity, direct or indirect ownership of at least a majority of
the stock or shares having the right to vote for the election of directors, and (b) in the case of a non-corporate entity, direct or indirect ownership of at least a majority of the equity interests with the power to direct the management and
policies of such non-corporate entity. 
 (b) “Control” shall mean with respect to any Technology or Intellectual Property
Right, the possession (whether by ownership or license, other than by a license granted pursuant to this Agreement) by a party of the ability to grant to the other party access, ownership, a license and/or a sublicense under such Technology or
Intellectual Property Right without violating the terms of any agreement or other arrangement with any third party as of the time such party would first be required hereunder to grant the other party such access, ownership, license, or sublicense.

 (c) “Deliverable” shall mean any of the items to be delivered by Microline to
Transenterix pursuant to the Work Plan, including the prototypes, Pre-Production Devices and Pilot Product Units. 
 (d)
“FDA” shall mean the United States Food and Drug Administration and any successor agency thereto, and its equivalent in countries other than the United States. 

(e) “Field” shall mean open, minimally invasive and laparoscopic surgery. 

(f) “FVS Product” shall mean the fully disposable flexible vessel sealing product that utilizes a (i) rotational nob,
(ii) introducer section that is rigid and (iii) flexible catheter based shaft with the working length and specifications determined in accordance with the Marketing Requirements Document (which for purposes of Section 8(a), shall
include the agreed working length plus or minus five (5) centimeters). 
 (g) “FVS Product Specifications” shall mean
the requirements and specifications for the FVS Product as agreed in writing by the Parties upon the completion of the Project (but in any event prior to the manufacture and delivery of the Pilot Product Units). 

(h) “Good Manufacturing Practices” shall mean all rules and standards contained in the then-current “Good Laboratory
Practices,” and/or “Good Manufacturing Practices,” as promulgated by the FDA or by any other Governmental Authority having jurisdiction over the development, marketing or sale of any Supply Product. 

(i) “Governmental Authority” shall mean any nation, territory, or government (or union thereof), foreign, domestic, or
multinational, any state, local, or other political subdivision thereof, and any bureau, court, tribunal, board, commission, department, agency, or other entity exercising executive, legislative, judicial, regulatory, or administrative functions of
government, including all taxing authorities and all European notified bodies, including notified bodies within the sense of Article 16 of the European Union Medical Device Directive 93/42/EEC, and all other entities exercising regulatory authority
over medical products or devices. 
 (j) “Intellectual Property Rights” shall mean all intellectual property rights in any
jurisdiction worldwide, including: (i) Patent Rights; (ii) rights associated with Technology that are works of authorship including copyrights, copyright applications, and copyright registrations; (iii) rights relating to the
protection of Technology as trade secrets, know-how or confidential information; and (iv) rights in any trade names, trademarks, service marks, domain names, logos, trade dress and brand features. 

(k) “Marketing Requirements Document” shall mean the description of the requirements for the development of the FVS Product,
as initially set forth on Exhibit A, and as reviewed and updated by the parties and/or the Project Managers. 
 (l) “Patent
Rights” shall mean all patents, patent applications and inventions on which patent applications are filed and all patents issuing therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations,
divisionals, continuations, continuations-in-part, reexamination certificates, substitutions or renewals, supplemental protection certificates, term extensions (under applicable patent law or other law), provisional rights and certificates of
inventions. 

  
 -2- 

 (m) “Pre-Production Devices” shall mean non-sterile, pre-production units of the
FVS Product that are not intended for human use and are to be delivered to Transenterix pursuant to the Work Plan in order to provide proof of principle examples of future sterile FVS Products. 

(n) “Pilot Product Units” shall mean sterile units of the FVS Product for initial clinical demand that are to be delivered to
Transenterix pursuant to the Work Plan. 
 (o) “Project” shall mean the development work to be performed by Microline
pursuant to this Agreement. 
 (p) “Project Technology” shall mean any Technology conceived, created, made or reduced to
practice during the Term solely or jointly by or on behalf of Microline or Transenterix, in each case directly arising out of the performance of this Agreement. 

(q) “Regulatory Approval” shall mean the 510(k) clearance requirement of the FDA for the FVS Products. 

(r) “Spider System” shall mean Transenterix’s existing SPIDER®
Surgical System, with the length and other characteristics described on Exhibit B. 
 (s) “Supply Products” shall
mean the FVS Products and the UPS Products. 
 (t) “Supply Product Specifications” shall mean the FVS Product Specifications
and the specifications for the UPS Product as set forth in the Marketing Requirements Document. 
 (u) “Technology” shall
mean any invention, conception, process, composition, device, apparatus, discovery, improvement thereon or other technology, whether or not patented or patentable or otherwise protectable by Intellectual Property Rights. 

(v) “UPS Product” shall mean the current Microline Universal Power Supply product, with such changes to such product as described in
the Marketing Requirements Document. 
 (w) “Work Plan” shall mean the Work Plan, including the timeline and Work Plan
Budget, for development of the FVS Product as set forth on Exhibit C, as such Exhibit may be updated and amended during the Term as provided in this Agreement. 

2. DEVELOPMENT PROJECT 

(a) Agreement to Develop. Microline shall, in consideration of the payments to be made by Transenterix pursuant to this Agreement, use
commercially reasonable efforts to (i) design and develop the FVS Product in accordance with the Marketing Requirements Document, (ii) deliver the Deliverables as set forth in the Work Plan, including the prototypes, Pre-Production Devices
and Pilot Product Units, and (iii) otherwise comply with its obligations in the Work Plan and the Marketing Requirements Document. 

  
 -3- 

 (b) Transenterix’s Obligations. Transenterix shall use its commercially reasonable
efforts to perform any responsibilities allocated to it in the Work Plan. 
 (c) Program Directors. Microline and Transenterix shall
each designate a primary contact person (a “Program Director”), who shall be responsible for representing the interests of the appointing party with respect to the management of the Project. The initial Program Directors shall be
named in the Work Plan. Either party may change its Program Director upon written notice to the other party. The parties acknowledge and agree that the Program Directors shall have the authority to amend the Marketing Requirements Document and the
Work Plan on behalf of the parties upon mutual agreement. 
 (d) Design Meetings. The Program Directors shall meet periodically to
discuss the status of the Project at such times and in such locations or forms (e.g., telephone or video conference) as the parties shall agree. At such meetings, the parties shall review the progress of the Project as against the Work Plan and any
potential technical difficulties or potential need to revise the Work Plan or the Marketing Requirements Document. The Microline Program Director shall be responsible for recording the minutes of each meeting. Such minutes shall be circulated
promptly following the meeting for review and comment. Such minutes shall be deemed approved by both of the parties unless a party objects to the accuracy of such minutes by providing written notice to the other party’s Program Director within
ten (10) days of receipt of such minutes. 
 (e) Kick-Off Meeting. The first meeting of the Program Directors (the
“Kick-Off Meeting”) may take place before or as soon as practicable following the Effective Date; provided that the parties shall endeavor to hold such Kick-Off Meeting within fifteen (15) days after the Effective Date
or as mutually agreed by the parties. During the Kick-Off Meeting, the parties shall review the Marketing Requirements Document. Promptly after the Kick-Off Meeting, Microline shall update the Marketing Requirements Document to reflect any changes
agreed to by the parties during the Kick-Off Meeting for approval by both Program Directors. 
 (f) Changes to Marketing Requirements
Document or Work Plan. Except as provided herein, no changes to the Work Plan or Marketing Requirements Document shall be permitted without the written consent of both parties. If either party wishes to propose a change to the Work Plan or
Marketing Requirements Document, it shall submit a written request for such change, describing all anticipated changes in fees, costs, feasibility or delivery schedule that will result from such change. The parties shall then negotiate in good faith
the requested change, but neither party shall be under any obligation to agree to any change, and if the parties fail to agree to a change the Project shall continue unamended. 

(g) Development Costs. Microline shall use commercially reasonable efforts to design and develop the FVS Product in accordance with the
budget set forth in the Work Plan (“Work Plan Budget”). To the extent that Microline shall incur any capital costs or overruns not accounted for in the Work Plan Budget, such expenses shall be the sole responsibility of Microline
(and such overruns or costs shall not relieve Microline of any of its obligations to Transenterix hereunder). 

  
 -4- 

 (h) Subcontracting. Either party may subcontract its obligations under the Work Plan. Each
party shall be responsible for any act or omission of any of its subcontractors in connection with such subcontractor’s performance of such party’s obligations under this Agreement. Such subcontractors shall be bound by the confidentiality
and intellectual property obligations of the parties set forth in Section 14 of this Agreement. 
 3. DELIVERABLES AND TESTING;
REGULATORY APPROVAL 
 (a) Deliverables. Microline shall use commercially reasonable efforts to deliver Deliverables conforming to
the Marketing Requirements Document to Transenterix in accordance with the Work Plan (and the timeframes set forth therein). Upon delivery of a Deliverable, Microline shall also deliver to Transenterix copies of all associated design documentation,
test data, reports, and any other information that is reasonably required by Transenterix in order to understand and review such Deliverable. 

(b) Review of Deliverables. Upon delivery of any Deliverable to Transenterix, Transenterix shall promptly, but within no more than
fifteen (15) business days, (i) inspect, review and test each Deliverable and (ii) accept or reject such Deliverable by written notice to Microline. Transenterix shall accept all Deliverables delivered in conformity with the Marketing
Requirements Document, but may reject any Deliverable that fails to conform with the Marketing Requirements Document. In the event Transenterix rejects any Deliverable, it shall provide the reasons for such rejection to Microline. Microline shall
have up to forty-five (45) days following such rejection to remedy any deficiencies in such Deliverable and to re-deliver such Deliverable to Transenterix. The parties shall repeat the procedures described in this Section 3(b) until the
Deliverable, based on the good faith determination of Transenterix, conforms to the Marketing Requirements Document. 
 (c) Regulatory
Approval. Microline shall apply for and use commercially reasonable efforts to obtain at its expense (i) Regulatory Approval for the use of the FVS Product in the United States and (ii) a 510(k) clearance for a FVS Product with a 5
and/or 7 (as determined by Microline) millimeter vessel sealing indication (the “5MM Clearance” and the “7MM Clearance”, respectively). Microline shall keep Transenterix informed as to the status of its applications
for such Regulatory Approval, 5 MM Clearance and/or the 7MM Clearance (as applicable)). Microline shall use commercially reasonably efforts to obtain regulatory approvals for jurisdictions outside of the United States as reasonably requested by
Transenterix at Transenterix’s expense. Microline shall provide all information related to the FVS Product reasonably requested by Transenterix if Transenterix elects to pursue regulatory approvals in jurisdictions outside of the United States,
including, without limitation, the technical file for CE/European approval. Transenterix shall cooperate with Microline relating to all material issues, amendments, supplements, and other matters respecting all regulatory approvals for the FVS
Product described in this Section 3(c). 
 4. SUPPLY RELATIONSHIP 

(a) Purchase and Sale. During the period beginning on the date that Microline delivers five hundred (500) Pilot Product Units to
Transenterix in compliance with the Warranties (“Pilot Product Delivery Date”) and ending on the third (3rd) anniversary of the Pilot Product Delivery Date (such period, the
“Supply Period”), Microline agrees to manufacture and sell to Transenterix all of its requirements, and Transenterix agrees to purchase, all of its requirements for the Supply Products at the prices set forth on Exhibit D, in
each case subject to the other terms and conditions of this Agreement. 

  
 -5- 

 (b) Forecasts. Subject to Section 4(c), each quarter, Transenterix will provide
Microline non-binding, rolling twelve (12) month forecasts for its requirements for the Supply Products (which shall become binding if not amended by Transenterix ninety (90) days prior to the commencement of the forecasted period).
Microline shall use commercially reasonable efforts to accommodate such forecasts and provide the required Supply Products in accordance with the forecasts provided by Transenterix (timeframe and volume), subject to a reasonable maximum monthly
order limit to be determined by the parties in good faith. Notwithstanding the foregoing, (i) Microline shall meet Transenterix’s volume requirements for the Supply Products in any given quarter provided that the volume for such quarter is
not in excess of twenty percent (20%) from the previous quarter, and (ii) Microline shall provide the Supply Products to Transenterix on the dates described in the binding forecasts. Microline covenants and agrees with Transenterix to use
its commercially reasonable efforts to accommodate any change in the forecasts requested by Transenterix (i.e., increases, decreases, timing of delivery, etc.). 

(c) Product Minimums. Notwithstanding anything to the contrary contained in this Agreement, during each of the first three
(3) twelve (12) month periods following the date that Microline receives the Regulatory Approval (collectively, the “Minimum Period”), Transenterix shall purchase at least 75% of the minimum number of Supply Products set
forth on Exhibit E, which shall become 100% of such minimum number upon the obtaining of 5MM Clearance or 7MM Clearance, prorated for the 12 month period based on the month in which such clearance was obtained (the “Minimum
Products”). In the event that this Agreement is terminated prior to the expiration of the Minimum Period other than by Transenterix in accordance with Section 15(b) or 15(d)(ii), Transenterix shall pay to Microline, for each Minimum
Product not purchased by Transenterix during the Minimum Period, an amount equal to (i) the then-current price of such Minimum Product multiplied by (ii) the profit margin achieved by Microline with respect to such Minimum Product
as of the effective date of such termination, as certified by Microline. During any Renewal Term (as such term is defined in Section 15(a)), Transenterix shall purchase the cumulative minimum number of Supply Products set forth on Exhibit
E for such Renewal Term (the “Renewal Minimum Products”). In the event that this Agreement is terminated prior to the expiration of such Renewal Term other than by Transenterix in accordance with Section 15(b), Transenterix
shall pay to Microline, for each Renewal Minimum Product not purchased by Transenterix during the Renewal Term, an amount equal to (A) the then-current price of such Renewal Minimum Product multiplied by (B) the profit margin
achieved by Microline with respect to such Renewal Minimum Product as of the effective date of such termination, as certified by Microline. 

(d) Improvements to UPS Products. Microline may notify Transenterix in writing of any improvement made by Microline to the UPS Products
during the Term (“Improvements Notice”), which Improvements Notice shall contain a reasonably detailed description of such improvement. If Transenterix notifies Microline in writing (“Election Notice”) within thirty
(30) days after the receipt of such Improvements Notice that Transenterix desires to incorporate such improvement into the UPS Products being supplied to Transenterix hereunder, the parties shall negotiate in good faith an adjustment to the
price of such UPS Products to reflect such improvement. To the extent that the parties cannot agree upon such an adjustment within sixty (60) days following Microline’s receipt of the Election Notice, such adjustment shall be determined in
accordance with Section 16(e). 

  
 -6- 

 (e) Inventory Reports. Within fifteen (15) days following each quarter during the
Term, Transenterix shall provide Microline with an inventory report for such quarter in such form as Microline may reasonably request, along with a short summary of Transenterix’s marketing and sales plans for the Supply Products. 

5. SHIPPING, RISK OF LOSS, ACCEPTANCE 

(a) Shipment. Microline shall: (i) ship Supply Products in accordance with Section 4(b) to Transenterix’s address as
specified in Section 16(i); (ii) enclose a packing memorandum with each shipment and, when more than one (1) package is shipped, identify the package containing the memorandum; (iii) forward bills of lading and shipping notices
with invoices; and (iv) invoice Transenterix by mailing or otherwise transmitting invoices, bills, and notices to Transenterix’s address as specified in Section 16(i). 

(b) Shipping Point, Risk of Loss. Microline shall pack the Supply Products in accordance with good commercial practice to avoid damage
in transit. Supply Products ordered by Transenterix shall be shipped by Microline FOB Beverly, Massachusetts, with the carrier and to Transenterix’s address as specified in Section 16(i). The Supply Products shall be sent from Microline
and received by Transenterix sterile, finished, supply boxed and packaged with appropriate Transenterix labeling (unless otherwise specified by Transenterix) so that Transenterix can ship the Supply Products directly to its customers. 

6. SUPPLY PRODUCT WARRANTIES 

(a) Supply Product Warranty. Microline represents and warrants to Transenterix that (i) all Supply Products (and the Pilot Product
Units) will function with other Supply Products (i.e., the FVS Product will function with the UPS Product, and vice versa), conform in all material respects to the applicable Supply Product Specifications, will conform with the applicable Regulatory
Approval (and after obtained by Microline, the 5MM Clearance and/or 7MM Clearance, as applicable) and will be free from any material defects in materials and workmanship for a period of twelve (12) months from delivery thereof (the
“Shelf Life”), (ii) Microline will transfer good title to the Supply Products to Transenterix, and (iii) all documentation supplied with the Supply Products will be accurate (the warranties contained in
Section 6(a)(i), (ii) and (iii) collectively, the “Warranties”). At the reasonable request and expense of Transenterix, Microline shall use commercially reasonable efforts to extend the Shelf Life for the Supply
Products. 
 (b) Inspection and Acceptance. Within fifteen (15) days after delivery of a shipment of Supply Products,
Transenterix (or its end user customer) shall conduct a visual inspection of the quantity and outside of the packaging of each unit of sale received in such shipment and shall provide written notice to Microline identifying any (a) Supply
Product shortages or (b) Supply Products that substantially fail to conform with the Warranties (each of (a) and (b), a “Warranty Claim”). Except as otherwise set forth below, any Supply Product for which a Warranty

  
 -7- 

 
Claim has not been received by Microline within the fifteen (15) day period shall be deemed to have been accepted by Transenterix. Transenterix’s acceptance of such Supply Product shall
be deemed to waive any claims other than claims brought during the Shelf Life of such Supply Product arising solely out of such Supply Product’s substantial failure to comply with any of the Warranties (and not arising solely out of
Transenterix’s or any end-user’s storage, handling, modification, misuse, marketing, export, import, advertising, labeling, distribution or sale of such Supply Product) (a “Specifications Claim”). 

(c) End-User Procedures. Whenever Transenterix shall sell a Supply Product it shall instruct the purchaser of such Supply Product to
contact Transenterix customer service for general support for such Supply Product. Transenterix shall provide general support and maintenance for such Supply Product; provided that if such Supply Product is returned to Transenterix due to a
Warranty Claim or a Specifications Claim, Transenterix shall provide such Supply Product(s) to Microline within the time periods described in Section 6(b). Upon verification of such claim in accordance with Section 7(e), Microline shall
promptly repair or replace such Supply Product, at Microline’s sole cost and expense. 
 7. QUALITY, AUDIT AND RECORDS 

(a) Appointment of Quality Control Manager. Each party shall appoint a responsible Quality Control Manager who shall be responsible for
all communications with respect to quality control with the other party, including those relating to Supply Product qualification and inspection, testing and quality control procedures. 

(b) Quality Assurance Procedures. Microline shall adopt and maintain quality assurance procedures to ensure that all Supply Products
manufactured under this Agreement conform to the applicable Supply Product Specifications (the “QA Procedures”). 
 (c)
Government Inspections. Microline agrees to provide access to its facilities at any time to FDA representatives or representatives from any other Governmental Authorities (including notified bodies) having appropriate jurisdiction for
inspection or other purposes, on any notice period required by the FDA or any other Governmental Authority. In addition, if the facilities used by Microline to manufacture the Supply Products are the subject of an audit or inspection by the FDA or
similar Governmental Authority, Microline shall notify Transenterix and if possible under the circumstances, Transenterix shall have the right to be present during such audit or inspection. 

(d) Records. Microline shall keep complete, accurate and detailed original records pertaining to the manufacture of the Supply Products
hereunder. Records shall be maintained for the longer of (i) any period required under applicable law; and (ii) a period of two (2) years after expiration or termination of this Agreement. Microline shall make available to
Transenterix such records without unreasonable delay to the extent reasonably requested and required by Transenterix to comply with its regulatory and other legal and reasonable business requirements. 

  
 -8- 

 (e) Microline Personnel. During the Shelf Life of each Supply Product delivered hereunder,
Microline shall provide, at the request of Transenterix and at no additional cost to Transenterix, technically competent personnel of Microline to assist in the identification and resolution of any performance problems with the Supply Products in
accordance with Microline’s regulatory procedures. 
 8. EXCLUSIVITY. 

(a) Microline Exclusivity; Changes to FVS Product. Microline agrees that it shall develop the FVS Product exclusively for, and supply
the FVS Product exclusively to, Transenterix for use with the Spider System in the Field. Transenterix acknowledges and agrees that nothing herein shall preclude Microline from conducting any development efforts, or from using any Technology or
Intellectual Property Rights, in each case to research, develop or commercialize products (other than the FVS Product to be used with the Spider System) in the Field. Microline covenants and agrees that it shall promptly refer all inquiries
regarding the FVS Product for use with the Spider System in the Field to Transenterix. Microline agrees that it will not supply the FVS Product for use with the Spider System to any third party (other than Transenterix), whether directly or
indirectly, for use in the Field. Microline acknowledges that any continuing and material breach of this Section 8(a) may cause Transenterix irreparable harm for which damages may not be an adequate remedy, and accordingly Microline hereby
agrees that the issuance of an injunction or other equitable relief may be appropriate to restrain any such breach or threatened breach. 

During the Term, Transenterix may request that Microline consider the development of a flexible sealing vessel product (other than the FVS
Product) for use with the Spider System in the Field. In the event that Microline desires to develop such a product, the parties shall use good faith efforts to negotiate a development and supply arrangement with development payments, supply
minimums and other terms acceptable to the parties. 
 (b) Transenterix Exclusivity. During the Term, and except as set forth in
Section 8(c), Transenterix agrees that it shall purchase all FVS Products and UPS Products, and any other tissue sealing and power supply products for use with the Spider System, exclusively from Microline. 

(c) Alternate Suppliers. In the event that either (i) Microline shall determine that it no longer has the capability to manufacture
Supply Products for Transenterix or (ii) Microline fails to supply at least 50% of the binding forecasts for two consecutive quarters (unless due to reasons beyond the reasonable control of Microline), in each case in accordance with this
Agreement, then either Microline shall provide written notice thereof to Transenterix promptly after making such determination in Section 8(c)(i) or Transenterix will provide notice of such failure to supply in Section 8(c)(ii) (which
Microline can dispute). Within sixty (60) days after such notice (or if disputed, after resolution of such dispute), Microline shall provide Transenterix with written notice (the “Alternative Supplier Notice”) identifying one
or more third party manufacturer(s) (each, an “Alternative Supplier”) from which Transenterix may purchase the Supply Products. If Microline fails to so deliver the Alternative Supplier Notice (or if the Alternative Supplier(s)
identified in the Alternative Supplier Notice cannot or will not deliver the Supply Products in accordance with Transenterix’s minimum forecasts and at or less than the pricing set forth in this Agreement, in Transenterix’s reasonable
discretion), then Transenterix may choose one or more Alternative Suppliers in its sole discretion. Promptly after the selection of an Alternative Supplier (or another supplier chosen by Transenterix pursuant to the immediately preceding sentence),
Microline shall provide such alternative supplier with sufficient information to permit such alternative supplier to manufacture the Supply Products. 

  
 -9- 

 9. COMMERCIALIZATION OF SUPPLY PRODUCTS 

(a) Commercialization of Supply Products. Except as otherwise provided in this Agreement, Transenterix shall have sole responsibility
for, and sole discretion with respect to, the commercialization of the Supply Products as long as it does not alter or modify the Supply Products, and it provides for the use of the Supply Products solely with its Spider System in accordance with
the applicable Regulatory Approval (or 5MM Clearance and/or 7MM Clearance as applicable) and other use specifications as provided by Microline. 

(b) Use of Trademarks. 

(i) Transenterix Marks. All Supply Products ordered by Transenterix under this Agreement shall bear solely such trademarks, service
marks, trade names and logo identifications owned by or licensed to Transenterix as Transenterix shall specify (the “Transenterix Marks”); provided that all Supply Products shall bear the trademarks of Microline and/or its
Affiliates (the “Microline Marks”) as reasonably requested by Microline, which Microline Marks shall be displayed less prominently than the Transenterix Marks. Microline shall have no right or license to use any Transenterix Marks
(other than to affix them to the packaging and labeling of the Supply Products sold to Transenterix under this Agreement). All goodwill relating to or developed with respect to any Transenterix Marks shall belong exclusively to Transenterix or its
Affiliates. Microline will not challenge the validity of any such Transenterix Mark or use a mark that is deceptively similar to any of the Transenterix Marks. 

(ii) Microline Trademark License. Microline hereby grants to Transenterix a non-exclusive, non-transferable, worldwide, royalty-free
license to use the Microline Marks in connection with Transenterix’s marketing and sale of the Supply Products. All goodwill associated with the foregoing license shall inure to the benefit of Microline and its Affiliates, and Microline shall
have sole control of, and responsibility for, any applications and registrations for the Microline Marks. Transenterix shall use the Microline Marks in accordance with Microline’s reasonable guidelines with respect to trademark usage of the
Microline Marks, as provided to Transenterix upon reasonable prior notice. 
 (c) Labeling. Transenterix shall provide Microline with
any labeling or product literature to be used in connection with any Supply Product at least ninety (90) days prior to the first commercial sale of such Supply Product. Transenterix shall give full consideration to any comments received from
Microline with respect to such labeling and product literature. Thereafter, Transenterix shall provide Microline with notice describing any material change to any such labeling or product literature at least ninety (90) days prior to the first
incorporation of such material change, and shall give full consideration to comments received from Microline with respect to such material change. 

  
 -10- 

 10. PAYMENTS 

(a) License Fees. In consideration of the license rights granted to Transenterix pursuant to this Agreement, Transenterix shall pay
Microline non-refundable license fees as follows: 
 (i) Transenterix shall pay Microline $250,000 within two (2) business days of the
Effective Date; 
 (ii) Transenterix shall pay Microline $200,000 within two (2) business days of delivery of twenty five
(25) Pre-Production Devices (in accordance with the Work Plan and the Marketing Requirements Document) (the “Prototype Date”); 

(iii) Transenterix shall pay Microline $100,000 within two (2) business days of receipt by Microline of Regulatory Approval for use of a
FVS Product; 
 (iv) Transenterix shall pay Microline $150,000 within two (2) business days of receipt by Microline of 5MM Clearance;
and 
 (v) Transenterix shall pay Microline $150,000 within two (2) business days of receipt by Microline of 7MM Clearance. 

(b) Payments for Development Milestones. In consideration of the work to be conducted by Microline pursuant to the Work Plan,
Transenterix shall pay Microline non-refundable milestone payments as set forth below: 
 (i) Transenterix shall pay Microline $250,000
within two (2) business days of the later of the Kick-Off Meeting or the Effective Date; 
 (ii) Transenterix shall pay Microline
$250,000 within two (2) business days of the date that Microline has achieved the specific stage of development of the FVS Product prior to delivery of the Pre-Production Devices that is described in the Work Plan as the “Design
Review”; 
 (iii) Transenterix shall pay Microline $125,000 within two (2) business days of the Prototype Date; and 

(iv) in addition to the amounts owed with respect to such Pilot Product Units pursuant to Sections 4(a) and 10(c), Transenterix shall pay
Microline $125,000 within two business days of delivery of five hundred (500) Pilot Product Units in compliance with the Warranties. 

(c) Supply Products. 
 (i)
Microline shall invoice Transenterix within thirty (30) days following each shipment of Supply Products in accordance with the shipping terms set forth in Section 4 above. Prices shall be as set forth on Exhibit D, and Transenterix
shall pay all invoiced amounts in accordance with such pricing terms within thirty (30) days of receipt of an invoice therefor. 

  
 -11- 

 (ii) Each invoice shall contain (A) Microline’s name and the invoice date,
(B) the type, price, and quantity of the Supply Products actually delivered, (C) the name (where applicable), title, phone number, and complete mailing address of the responsible official to whom payment shall be sent, and (D) other
substantiating documentation or information as may reasonably be required by Transenterix from time to time. 
 11. REPRESENTATIONS AND
WARRANTIES 
 (a) Development Warranty. Microline represents and warrants to Transenterix that it will develop the FVS Products
diligently, with reasonable skill and care, and using the services of appropriately skilled and trained workers, and in compliance with Good Manufacturing Practices and the QA Procedures. 

(b) Representations and Warranties of Microline. Microline represents and warrants that as of the Effective Date (i) Microline has
the full power, right and authority to enter into this Agreement, carry out its obligations under this Agreement, and grant the rights granted to Transenterix hereunder; (ii) Microline has not previously granted and will not in the future grant
any rights in or to the Microline Background Technology (as defined in Section 12(a)), Microline Project Technology (as defined in Section 12(b)), FVS Products or the UPS Products to a third party which are inconsistent with the rights
granted to Transenterix herein; and (iii) Microline has not received any communications alleging that Microline’s use of Microline Background Technology relating to the FVS Products or UPS Products would violate Intellectual Property
Rights of any third party. 
 (c) Representations and Warranties of Transenterix. Transenterix represents and warrants that as of the
Effective Date, (i) it has the full power, right and authority to enter into this Agreement and to carry out its obligations hereunder; (ii) Transenterix has not previously granted and will not in the future grant any rights in or to the
Transenterix Background Technology (as defined in Section 12(a)), Transenterix Project Technology (as defined in Section 12(c)) or Spider System to a third party which are inconsistent with the rights granted to Microline herein;
(iii) Transenterix has obtained all United States regulatory approvals from, has made all necessary and appropriate applications and other submissions to, and has prepared and maintained all records, studies and other documentation needed to
maintain and demonstrate compliance with the requirements of, the FDA and other United States Governmental Authorities for its current and past business activities relating to the Spider System; and (iv) Transenterix has not received any
communications alleging that Transenterix’s use of Transenterix Background Technology relating to the Spider System would violate Intellectual Property Rights of any third party. 

(d) Exclusion of Any Other Warranties of Microline. The representations and warranties contained in this Agreement are made in lieu of
all other representations or warranties, express or implied, by Microline, whether oral or written. Microline hereby disclaims all implied warranties, including the warranties of merchantability and fitness for a particular purpose. 

12. INTELLECTUAL PROPERTY 

(a) Background Technology. Each party shall own and retain all right, title and interest in and to all Technology, and all Intellectual
Property Rights therein, Controlled by such party that does not constitute Project Technology or that is otherwise created prior to or independently from the Project (“Microline Background Technology” and “Transenterix
Background Technology,” respectively). 

  
 -12- 

 (b) Microline Project Technology. Microline shall own all right, title and interest in and
to all Project Technology, and all Intellectual Property Rights therein, related to the FVS Products or the UPS Products or to the development efforts relating to such FVS Products or UPS Products (“Microline Project Technology”).

 (c) Transenterix Project Technology. Transenterix shall own all right, title and interest in and to all Project Technology, and all
Intellectual Property Rights therein, related to the Spider System, but excluding any Microline Project Technology (“Transenterix Project Technology”). 

(d) Assignment of Technology. Subject to the licenses and other rights specifically set forth in this Agreement, to the extent either
party (such party, the “Assigning Party”) obtains any title or similar ownership interest in any Project Technology, or any Intellectual Property Rights therein, that is to be owned by the other party (the “Assigned
Party”) in accordance with the terms and conditions of this Agreement, the Assigning Party hereby assigns and, to the extent such assignment cannot be made at present, agrees promptly to assign, to the Assigned Party all of the Assigning
Party’s title and other ownership interest in and to such Project Technology and Intellectual Property Rights. The Assigning Party shall execute and procure such documents, including short-form assignments and assignments of patent applications
and patents, and take such other actions as may be reasonably requested from time to time by the Assigned Party to obtain for its own benefit appropriate protections for Intellectual Property Rights with respect to such Project Technology, or
otherwise to transfer or confirm the transfer, in whole or in part, as the case may be, of such Project Technology and the related Intellectual Property Rights for the benefit of the Assigned Party. Each party represents and covenants that all of
its employees, consultants and agents, and all third parties acting on behalf of such party in performing its obligations under this Agreement, shall be obligated under a binding written agreement to assign to such party all Project Technology and
Intellectual Property Rights conceived, created, made or reduced to practice by such employees, consultants, agents and third parties in connection with the Project. 

(e) Prosecution and Enforcement of Project Technology. The owner of any Project Technology (the “Owner”) shall have the
sole right to prepare, file applications on and registrations for, prosecute, obtain, maintain, defend and enforce all Intellectual Property Rights in such Project Technology in such manner as the Owner deems appropriate in its sole discretion,
including incurring all expenses required for such purposes. Notwithstanding the foregoing, (i) Microline shall use commercially reasonable efforts to preserve, obtain and maintain all Intellectual Property Rights for Microline Project
Technology and for Microline Background Technology related to the FVS Products or the UPS Products and to file patent applications covering any inventions included within such technology, in each case in its reasonable discretion and
(ii) Transenterix shall use commercially reasonable efforts to preserve, obtain and maintain all Intellectual Property Rights for Transenterix Project Technology and for Transenterix Background Technology related to the Spider System and to
file patent applications covering any inventions included within such technology, in each case in its reasonable discretion. The non-Owner party shall cooperate fully at its 

  
 -13- 

 
own expense in those activities by the Owner, which cooperation shall include, without limitation, (i) promptly executing all papers and instruments or requiring the non-Owner’s
employees, agents and third parties acting on the non-Owner’s behalf to execute such papers and instruments as are reasonable and appropriate so as to enable the Owner to prepare, file, prosecute, obtain, maintain, defend and enforce such
Intellectual Property Rights, and (ii) promptly informing the Owner of matters that may affect those activities (including any prior art that may be material to Patent Rights contained in the such Intellectual Property Rights). 

(f) License Grants. 
 (i)
Subject to the terms and conditions of this Agreement, Microline hereby grants to Transenterix a worldwide, non-exclusive license or sublicense (as the case may be) in the Field, without the right to sublicense except to subcontractors as permitted
by Section 2(g), under all Intellectual Property Rights Controlled by Microline to use the Microline Background Technology and Microline Project Technology, but only as necessary to exercise its rights or fulfill its obligations
under this Agreement. The license granted pursuant to this Section 12(0(i) is only transferable in accordance with the terms and conditions of Section 16(c). 

(ii) Subject to the terms and conditions of this Agreement, Transenterix hereby grants to Microline a worldwide, non-exclusive license or
sublicense (as the case may be) in the Field, without the right to sublicense except to subcontractors as permitted by Section 2(g), under all Intellectual Property Rights Controlled by Transenterix, to use Transenterix Background Technology
and Transenterix Project Technology, but only as necessary to exercise its rights or fulfill its obligations under this Agreement. The license granted pursuant to this Section 12(f)(ii) is only transferable in accordance with the
terms and conditions of Section 16(c). 
 (g) No Implied Licenses. 

(i) Transenterix acknowledges and agrees that, as between the parties and notwithstanding anything to the contrary in this Agreement,
Microline owns all right, title and interest in and to, including all Intellectual Property Rights pertaining to, all Microline Background Technology and Microline Project Technology, and that under this Agreement, Transenterix shall acquire no
right, title or interest in or to any of the foregoing, by implication, estoppel or otherwise, other than the license rights expressly granted herein or as otherwise expressly provided herein. 

(ii) Microline acknowledges and agrees that, as between the parties and notwithstanding anything to the contrary in this Agreement,
Transenterix owns all right, title and interest in and to, including all Intellectual Property Rights pertaining to, all Transenterix Background Technology and Transenterix Project Technology, and that under this Agreement, Microline shall acquire
no right, title or interest in or to any of the foregoing, by implication, estoppel or otherwise, other than the license rights expressly granted herein or as otherwise expressly provided herein. 

  
 -14- 

 13. INDEMNIFICATION AND INSURANCE 

(a) Microline Product Liability Indemnification. Microline shall defend, indemnify and hold harmless Transenterix, its Affiliates, their
permitted successors and assigns and their respective directors, officers, employees, and agents from and against all liabilities, damages, losses, settlements, claims, actions, suits, penalties, fines, costs and expenses (including reasonable
attorneys and professionals’ fees) (“Liabilities”) resulting from any and all claims by third parties for loss, damage or injury (including death) caused by (i) any Warranty Claim or Specifications Claim,
(ii) Microline’s material breach of this Agreement, (iii) Microline’s gross negligence or willful misconduct or (iv) any other defect to any Supply Product directly attributable to Microline or its subcontractors or
suppliers, except, in the case of clauses (i) through (iv), to the extent such Liabilities are caused by (A) the storage, handling, modification, misuse, marketing, export, import, advertising, labeling, distribution or sale by
Transenterix of any Supply Product, (B) Transenterix’s material breach of this Agreement, (C) Transenterix’s gross negligence or willful misconduct or (D) any Transenterix product containing or used in conjunction with a
Supply Product, including, without limitation, the Spider System (“Transenterix Product”). 
 (b) Transenterix Product
Liability Indemnification. Transenterix shall defend, indemnify and hold harmless Microline, its Affiliates, their permitted successors and assigns and their respective directors, officers, employees, and agents from and against all Liabilities
resulting from any and all claims by third parties for loss, damage or injury (including death) caused by (i) the storage, handling, modification, marketing, export, import, advertising, labeling, distribution or sale by Transenterix of any
Supply Product, (ii) Transenterix’s material breach of this Agreement, (iii) Transenterix’s gross negligence or willful misconduct or (iv) any Transenterix Product, except, in the case of clauses (i) through (iv), to
the extent such Liabilities are caused by (A) any Warranty Claim or Specifications Claim, (B) Microline’s material breach of this Agreement, (C) Microline’s gross negligence or willful misconduct or (D) any other defect
to any Supply Product directly attributable to Microline or its subcontractors or suppliers. 
 (c) Procedure. The parties will follow
the following procedures with respect to any indemnification provided pursuant to this Agreement: 
 (i) Any person claiming indemnification
under this Agreement (the “Indemnified Party”) will give Microline or Transenterix, as the case may be (the “Indemnitor”), written notice of any claim promptly after receipt by such Indemnified Party of notice
thereof. Any delay in giving notice hereunder which does not materially prejudice the Indemnitor will not affect the Indemnified Party’s rights to indemnification hereunder. The Indemnitor will have the right to defend the Indemnified Party
against any claim with counsel of its choice reasonably satisfactory to the Indemnified Party so long as (A) the Indemnitor notifies the Indemnified Party in writing, within fifteen (15) days after the Indemnified Party has given notice of
the claim, of the Indemnitor’s election to defend the claim and of the identity of the Indemnitor’s counsel, (B) the Indemnitor provides the Indemnified Party with evidence reasonably acceptable to the Indemnified Party that the
Indemnitor will have the financial resources to defend against the claim and fulfill its indemnification obligations hereunder, (C) the claim involves only money damages and does not seek an injunction or other equitable relief, and
(D) the Indemnitor conducts the defense of the claim actively and diligently. 

  
 -15- 

 (ii) So long as the Indemnitor is conducting the defense of the claim in accordance with clause
(i) above, (A) the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of the claim, (B) the Indemnified Party will not consent to the entry of any judgment or enter into any
settlement with respect to the claim without the prior written consent of the Indemnitor (which consent shall not be unreasonably withheld) and (C) the Indemnitor will not consent to the entry of any judgment or enter into any settlement with
respect to the claim without the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld). 
 (iii)
In the event any of the conditions in clause (i) above is or becomes unsatisfied, (A) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, the claim in any manner
it reasonably may deem appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnitor in connection therewith), (B) the Indemnitor will reimburse the Indemnified Party promptly and periodically for the
costs of defending against the claim (including reasonable attorneys’ fees and expenses), and (C) the Indemnitor will remain responsible for any Liabilities the Indemnified Party may suffer resulting from, arising out of, relating to, in
the nature of, or caused by the claim to the fullest extent provided in this Section 13. 
 (d) Insurance. 

(i) Microline will procure and maintain at its expense comprehensive general liability insurance with a reputable insurer in amounts of not
less than $3 million per incident and $5 million annual aggregate. Such comprehensive general liability insurance will (a) provide product liability coverage, (b) provide broad form contractual liability coverage extending to
Microline’s indemnification obligations under this Section 13, (c) contain no products or completed operations exclusions, (d) be in occurrence form and (e) name Transenterix as an additional insured. Microline will maintain
such insurance during the Term and for a period of at least five (5) years thereafter. Microline will provide Transenterix with written evidence of such insurance upon the request of Transenterix, and will provide Transenterix with written
notice at least thirty (30) days prior to any cancellation, non-renewal, reduction or other material change in such insurance. 
 (ii)
Transenterix will procure and maintain at its expense comprehensive general liability insurance with a reputable insurer in amounts of not less than $3 million per incident and $5 million annual aggregate. Such comprehensive general liability
insurance will (a) provide product liability coverage, (b) provide broad form contractual liability coverage extending to Transenterix’s indemnification obligations under this Section 13, (c) contain no products or completed
operations exclusions, (d) be in occurrence form and (e) name Microline and its Affiliates as an additional insureds. Transenterix will maintain such insurance during the Term and for a period of at least five (5) years thereafter.
Transenterix will provide Microline with written evidence of such insurance upon the request of Microline, and will provide Microline with written notice at least thirty (30) days prior to any cancellation, non-renewal, reduction or other
material change in such insurance. 

  
 -16- 

 14. CONFIDENTIALITY 

(a) “Confidential Information” means, as to any party (the “Disclosing Party”), all confidential information
provided by or on behalf of such party to the other party (the “Receiving Party”), including any Technology, the terms of this Agreement, and information relating to its business operations or technology, whether disclosed orally or
in writing and whether or not marked as being confidential, except any portion thereof which: (i) is known, and can be shown to have been known, by the Receiving Party (other than from the Disclosing Party hereunder) before receipt thereof
under this Agreement; (ii) is disclosed to the Receiving Party by a third person who has a right to make such disclosure without any obligation of confidentiality to the Disclosing Party hereunder; (iii) is or becomes generally known to
the public through no fault of the Receiving Party; or (iv) is independently developed by the Receiving Party, without access to other Confidential Information of the Disclosing Party, as evidenced by the Receiving Party’s written records.

 (b) Nondisclosure. Confidential Information of each Disclosing Party is the exclusive property of such Disclosing Party.
Confidential Information of a Disclosing Party may be used by the Receiving Party only in connection with the performance of any obligations or the exercise of any rights under this Agreement. Confidential Information of the Disclosing Party shall
not be disclosed to a third party by the Receiving Party without the prior written consent of the Disclosing Party or as authorized by this Agreement. Each Receiving Party will protect the confidentiality of the Confidential Information of the
Disclosing Party with at least the same degree of care that it uses to protect the confidentiality of its own proprietary and confidential information, including by entering into appropriate confidentiality agreements with employees, agents,
independent contractors and subcontractors. Access to and use of Confidential Information will be restricted to those of Microline’s and Transenterix’s agents, employees or contractors engaged in a use permitted under this Agreement and
who have been apprised of the confidential nature of such information. Each Receiving Party will be responsible for any breaches of this Section 14 by its agents, employees or contractors. Confidential Information may not be copied or
reproduced without the Disclosing Party’s prior written consent, except as necessary for use in connection with this Agreement. 
 (c)
Disclosure Upon Process. In the event either party receives a subpoena, or other validly-issued administrative or judicial process, requesting that Confidential Information of the other party be disclosed, it will promptly notify the other
party of such receipt and allow the other party appropriate time to apply for a protective order. The party receiving such request will thereafter be entitled to comply with such subpoena or other process, only to the extent required by law. 

(d) Publicity. The terms and conditions of this Agreement shall be Confidential Information of both parties, and shall not be disclosed
by either party without the prior written consent of the other, provided, however, that either party may in any event provide and disclose this Agreement to third parties in connection with any proposed financing or other corporate
transaction, subject to a usual and customary confidentiality agreement. Except as otherwise described in this paragraph, neither party shall make any public announcement of this Agreement except by mutual written consent. 

(e) Injunctive Relief. Each party acknowledges that any material breach of this Section 14 shall cause the other party irreparable
harm for which damages would not be an adequate remedy, and accordingly each party hereby agrees that the issuance of an injunction or other equitable relief is appropriate to restrain any such breach or threatened breach. 

  
 -17- 

 15. TERM AND TERMINATION 

(a) Term. This Agreement shall be effective on the Effective Date and shall continue in full force and effect until the expiration of
the Supply Period, unless terminated earlier as provided herein (the “Initial Term”). Unless terminated by either party by written notice given not less than sixty (60) days prior to the expiration of the Initial Term or any
then-current Renewal Term, the term of this Agreement shall automatically be extended for additional one (1) year periods (each, a “Renewal Term,” and the Initial Term and any Renewal Term, the “Term”).
Notwithstanding anything in this Agreement to the contrary, Microline covenants and agrees that it will not terminate this Agreement by written notice pursuant to this Section 15(a) during or prior to any Renewal Term as long as Transenterix
has purchased or is bound to purchase at a minimum the following quantities of FVS Products during the year prior to the applicable Renewal Term: 
  

			
	 Renewal Term
	  	 Quantity

	 First Renewal Term
	  	The greater of 7,500 FVS Products or 80% of the FVS Products purchased during the second year of the Supply Period
		
	 Second Renewal Term
	  	The lesser of 10,000 FVS Products or an amount of FVS Products that is 15% or more of the amount of FVS Products purchased by Transenterix from Microline during the third year of the Supply Period
		
	 Third Renewal Term
	  	The lesser of 15,000 FVS Products or an amount of FVS Products that is 15% or more of the amount of FVS Products purchased by Transenterix from Microline during the fourth year of the Supply Period

 (b) Termination for Breach. Notwithstanding any other provision of this Agreement, each party shall have
the right, in addition to any other rights and remedies available to such party, to terminate this agreement immediately by written notice to the other party if the other party breaches any material provision of this Agreement and fails to cure such
breach within thirty (30) days of the receipt by the breaching party of notice specifying the breach and requiring its remedy. The parties acknowledge that Transenterix’s failure to timely pay any undisputed amounts due hereunder (and any
disputed amounts upon resolution or in any event within ninety (90) days of when originally due) shall constitute a material breach. 

  
 -18- 

 (c) Termination for Bankruptcy. 

(i) Each party may terminate this Agreement immediately upon written notice to the other party if such other party shall (A) file in any
court or agency pursuant to any law of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that party or of its assets, (B) be
served with an involuntary petition in bankruptcy against it, filed in any such proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof, (C) be a party to any dissolution or liquidation, or
(D) make a general assignment for the benefit of its creditors. 
 (ii) Microline Bankruptcy. If this Agreement is terminated by
Transenterix in accordance with this Section 15(c), Microline shall grant, and hereby grants, to Transenterix a worldwide, non-exclusive, license in the Field under all Intellectual Property Rights Controlled by Microline to use the Microline
Background Technology and Microline Project Technology, but only as necessary to enable Transenterix to manufacture or commercialize the FVS Product or UPS Product. Such license shall terminate on the date that the Initial Term or
then-current Renewal Term (as applicable) would have expired had this Agreement not been terminated in accordance with this Section 15(c), provided, however, that during the six (6) month period following the termination of such license,
Transenterix shall have the right to sell any Supply Products purchased by Transenterix hereunder prior to the termination of this Agreement for which the Shelf Life has not expired, and provided further that Transenterix shall comply with the terms
and provisions of this Agreement in connection with the sale of such Supply Products. 
 (iii) Section 365(n). All rights and
licenses granted under or pursuant to this Agreement by ether party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”), licenses of rights to
“intellectual property” as defined under Section 101 of the Bankruptcy Code. The parties agree that the parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections
under the Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either party under the Bankruptcy Code, the party hereto that is not subject to such proceeding shall be entitled to
a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject party’s possession, shall be promptly delivered to it
(A) following any such commencement of a bankruptcy proceeding upon the non-subject party’s written request therefor, unless the party subject to such proceeding elects to continue to perform all of its obligations under this Agreement, or
(B) if not delivered under the immediately preceding clause (A), upon written request therefor by the non-subject party following the rejection of this Agreement by or on behalf of the party subject to such proceeding. 

(d) Termination for Convenience; FDA Approval. 

(i) Notwithstanding any other provision of this Agreement, Transenterix shall have the right to terminate this Agreement at any time after the
Pilot Product Delivery Date upon ninety (90) days’ written notice to Microline (and in such instance, Transenterix shall not be released from any payment obligations accruing prior to or in connection with such termination, including the
obligation to pay Microline the amounts specified in Section 4(c)). 

  
 -19- 

 (ii) Microline shall use commercially reasonable efforts to obtain the Regulatory Approval
within twelve (12) months after the Effective Date. Notwithstanding any other provision of this Agreement, Transenterix shall have the right to terminate this Agreement upon thirty (30) days’ written notice to Microline in the event
that Microline shall not have obtained such Regulatory Approval within fifteen (15) months of the Effective Date (unless Microline’s failure to obtain such Regulatory Approval is due to reasons beyond the reasonable control of Microline,
including any unforeseen regulatory or technical issues). Notwithstanding the immediately preceding parenthetical, if Microline has not procured the Regulatory Approval for any reason within eighteen (18) months after the Effective Date,
Transenterix may at its option terminate this Agreement upon ninety (90) days written notice to Microline. 
 (iii) Microline shall use
commercially reasonable efforts to obtain the 5MM Clearance or 7MM Clearance within nine (9) months after Microline’s receipt of the Regulatory Approval. Notwithstanding any other provision of this Agreement, Transenterix shall have the
right to terminate this Agreement upon thirty (30) days’ written notice to Microline in the event that Microline shall not have obtained such 5MM Clearance or 7MM Clearance within twelve (12) months after Microline’s receipt of
the Regulatory Approval, unless Microline’s failure to obtain such 5MM Clearance or 7MM Clearance is due to reasons beyond the reasonable control of Microline, including any unforeseen regulatory or technical issues. 

(e) Effect of Termination. Except as described in Section 15(c)(ii), upon any termination or expiration of the Agreement, each
party shall return and make no further use of any Confidential Information and materials (and all copies thereof) belonging to the other party, provided, however, that during the six (6) month period following such termination or expiration,
Transenterix shall have the right to sell any Supply Products purchased by Transenterix hereunder prior to such termination or expiration for which the Shelf Life has not expired, and provided further that Transenterix shall comply with the terms
and provisions of this Agreement in connection with the sale of such Supply Products. 
 (f) Survival. In addition to such other
provisions which by their nature reasonably are intended to survive any expiration or termination of this Agreement, the provisions of Sections 1, 7(d), 7(e), 10 (i.e., each sub-section survives only to the extent that prior to the date of
termination, Microline had fully met its obligations to Transenterix described in that sub-specific section), 11, 12, 13, 14, 15(c), 15(d), 15(e), 15(f) and 16, and any Exhibits or definitions referenced therein, shall survive any such expiration or
termination. 
 16. GENERAL 

(a) Entire Agreement. This Agreement, together with the attached Exhibits, shall constitute the entire Agreement between the parties
with respect to the subject matter hereof and supersedes all other prior and contemporaneous oral and written communications, agreements and understandings of the parties with respect to the subject matter hereof. In making this Agreement, the
parties have not made or relied upon any representations, understandings or other agreements not specifically set forth herein. 

  
 -20- 

 (b) Waivers; Amendments; Supplements. No waiver by either party of a breach of any
covenant or condition of this Agreement by the other party shall be construed to be a waiver of any succeeding breach of the same or any other covenant or condition. Except as otherwise expressly provided herein, this Agreement or any Exhibit
hereunder may not be changed or amended except by a writing expressly referring to this Agreement signed by both parties. 
 (c)
Assignment. Neither party may assign or otherwise transfer this Agreement, or any rights or obligations hereunder, to any third party without the prior written consent of the other, which consent will not be unreasonably withheld.
Notwithstanding the immediately preceding sentence, either party may assign this Agreement without consent of other party to an entity into which it is merged or consolidated or by which it is acquired, or which acquires the portion of its business
related to this Agreement; provided that in each case the acquirer agrees in writing to assume and fulfill the obligations of such party under this Agreement. 

(d) Choice of Law; Forum. This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of
the state of New York without regard to its principles of conflicts of laws. Subject to Section 16(e), any litigation arising from or relating to this Agreement shall be filed and prosecuted before a court of competent subject matter
jurisdiction located in the state of New York. The parties hereby consent to the jurisdiction of such courts over them, stipulate to the convenience, efficiency and fairness of proceeding in such courts, and covenant not to assert any objection to
proceeding in such courts based on any alleged lack of jurisdiction or any alleged inconvenience, inefficiency or unfairness of such courts. 

(e) Dispute Resolution. 

(i) In the event of any dispute, claim or controversy arising out of or relating to the interpretation of any provision of this Agreement, to
the performance of either party under this Agreement or to any other matter under or in connection with this Agreement, including any action in tort, contract or otherwise, at equity or law (a “Dispute”), either party may at any
time provide the other party written notice specifying the terms of such Dispute in reasonable detail. As soon as practicable after receipt of such notice, one or more senior executives from each party shall meet at a mutually agreed upon time and
location for the purpose of resolving such Dispute. Such senior executives shall engage in good faith discussions and/or negotiations for a period of up to thirty (30) days to resolve the Dispute or negotiate an interpretation or revision of
the applicable portion of this Agreement which is mutually agreeable to both parties, without the necessity of formal procedures relating thereto. During the course of such discussion and/or negotiation, the parties shall reasonably cooperate and
provide information that is not materially confidential in order so that each of the parties may be fully informed with respect to the issues in the Dispute. 

(ii) Any Dispute not resolved pursuant to clause (i) above shall be resolved exclusively by arbitration conducted in New York, New York
by a single arbitrator agreed between the parties, under the Commercial Arbitration Rules of the American Arbitration Association. If the parties cannot agree on a single arbitrator, either party shall have the right to give notice that the Dispute
shall be heard by three arbitrators, each party selecting one arbitrator and the two selecting a third. The arbitrator(s) shall have at least fifteen (15) years’ experience in medical device matters and shall have no conflicts of interest.
Each party shall bear its own costs of participating in the arbitration, and the costs and expenses of the arbitrators shall be shared equally. The decision of the arbitrator shall be binding and enforceable in any court of competent jurisdiction.

  
 -21- 

 (f) Independent Contractors. The relationship of Microline and Transenterix at all times
shall be solely that of independent contractors with respect to all matters arising under this Agreement. Nothing herein shall be deemed to establish a relationship of partnership, joint venture or employment between the parties. Transenterix shall
have no control or direction over Microline and any of its employees, consultants and subcontractors performing development or manufacturing hereunder. Any such employees, consultants and subcontractors shall not have any contractual relationship
whatsoever with Transenterix arising out of or by virtue of this Agreement, and Microline shall be responsible for compliance with all applicable employment related laws and regulations with respect to such persons, including without limitation
those governing hours of labor, working conditions, workers’ compensation, payment of wages, and the payment of any applicable taxes, such as unemployment, social security, and other payroll taxes. 

(g) Force Majeure. Neither party shall be liable for any delay or failure in performance of any obligations hereunder (other than
payment obligations) arising out of acts or events beyond its reasonable ability to foresee and avoid, including fires, labor disputes, embargoes, failure of suppliers, requirements imposed by Government regulation, civil or military authorities,
judicial decisions, acts of God or by the public enemy. 
 (h) Further Actions. Each party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

(i) Notices. All notices, demands, requests, approvals, consents or other communications to be given or delivered under this Agreement
shall be in writing and shall be deemed to have been given: (i) when delivered in person or by courier or confirmed facsimile; (ii) upon confirmation of receipt when sent by certified mail, return receipt requested; or (iii) upon
receipt when sent by reputable private international courier with established tracking capability (such as DHL, FedEx, or UPS), postage pre-paid, to the noticed party at the address set forth below, or such other address as a party may specify by
written notice to the other. 
 Notices shall be sent to Microline at: 

Microline Surgical, Inc. 
 800
Cummings Center, Suite 166T 
 Beverly, MA 01915 

Attention: President 
 Telecopier:
(978) 922-9209 
 with a required copy to: 

Foley Hoag LLP Seaport West 
 155
Seaport Boulevard 
 Boston, Massachusetts 02210 

Attention: Gil Arie, Esq. 

Telecopier No.: (617) 832-7000 

  
 -22- 

 and to Transenterix at: 

Transenterix, Inc. 
 635 Davis
Drive, Suite 300 
 Durham, North Carolina 27713 

Attention: Luke Roush 

Telecopier: (919) 765-8459 

with a required copy to: 

Forrest Firm, P.C. 
 4819 Emperor
Boulevard 
 Durham, North Carolina 27703 

Attention: James Forrest, Esq. 

Telecopier No.: (919) 313-4505 

(j) Captions, Section Headings. As used in this Agreement, “including” means “including but not limited to”, and
“herein”, “hereof”, and “hereunder” refer to this Agreement as a whole. The Section headings used hereof are for reference and convenience only, and shall not enter into the interpretation of this Agreement. Unless
otherwise expressly provided herein, any reference to a number of “days” hereunder shall refer to calendar days. 
 (k)
Severability. If any provision of this Agreement is determined to be invalid, illegal or otherwise unenforceable, then such provision will instead be construed to give effect to its intent to the maximum extent possible, and the validity,
legality and enforceability of the other provisions of this Agreement shall not be affected thereby. If, after application of the immediately preceding sentence, any provision of this Agreement is determined to be invalid, illegal or unenforceable,
such provision shall be severed, and after any such severance, all other provisions hereof shall remain in full force and effect. 
 (l)
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument. Execution and delivery of this Agreement and the
Exhibits hereto by any party via facsimile or e-mailed pdf shall be legal, valid and binding execution and delivery of such document for all purposes. 

- Signature Appear on the Following Page. - 

  
 -23- 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed under seal by their
duly authorized representatives as of the Effective Date 
  

									
	Transenterix, Inc.	 		 	Microline Surgical, Inc.
					
	By:	 	 /s/ Todd M. Pope
	 		 	By:	 	 /s/ Sharad H. Joshi

					
	Name:	 	 Todd M. Pope
	 		 	Name:	 	 Sharad H. Joshi

					
	Title:	 	 Chief Executive Officer
	 		 	Title:	 	 President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]